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ABSTRACT
Recognition of polymicrobial infections is becoming important for understanding differential
host responses to environmental exposures, vaccines, as well as therapeutics. Citrobacter
rodentium is a well-characterized model of infectious colitis with particular usefulness for
modeling human diarrheal disease or inflammatory bowel disease. Infection with Helicobacter
hepaticus is subclinical and persistent in C57BL/6 mice, but causes disease in susceptible strains
and immunodeficient mice. To test the hypothesis that subclinical persistent infection modulates
the host response to diarrheal disease a polymicrobial mouse model utilizing H. hepaticus and C.
rodentium was developed and characterized.
Concurrent infection has been shown to modulate disease outcome through several mechanisms
including: cross-reactivity between viral antigens; shifting T cell response from Thi to Th2 by
helminth infection; and induction of regulatory T cells that suppress host response. In this new
model of polymicrobial infection, a new paradigm in which persistent infection prolonged the
course of acute colitis associated with a deviation from Thl-biased disease to Thl 7 was observed.
In addition, Foxp3* naturally-occurring regulatory T cells (nT,,g) were markedly increased during
active colitis. The accumulation of nTreg was sustained when mice were persistently infected
with H. hepaticus, indicating on-going active colitis. Although persistent infection was able to
modulate host response, protective immunity to a subsequent C. rodentium infection was not
compromised. Persistent infection also modulated host response to soluble antigen by
preventing induction of oral tolerance to single bolus, but not to continuous, high-dose antigen
feeding.
Using H. hepaticus infection of C57BL/6 mice, models to investigate the immunomodulatory
potential of persistent infection on immunogenic responses of protective immunity to enteric
infection, host response to polymicrobial enteric infection, as well as tolerogenic responses to
soluble antigen were developed. These models establish baselines for further investigation into
the influences of persistent infection on host immune responses.
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Chapter 1
Introduction
Helicobacter hepaticus is a microaerophilic gram-negative spiral organism that
specifically infects mice (26, 85). First isolated from livers of SCID/NCr mice with active,
chronic hepatitis, and mucosa of the cecum and colon in SCID/NCr as well as A/JCr mice (26),
H. hepaticus primarily resides in the cecal mucosa (15, 31). Although infection of most strains of
immunocompetent mice show limited signs of clinical disease, infection of susceptible mouse
strains causes inflammation of the large intestines and liver leading to hepatocellular carcinoma
(4, 27, 37, 68, 85, 86, 88). In contrast, immunodeficient mice, particularly those lacking adaptive
immune functions, develop an IBD-like disease (13, 17, 19, 39, 40, 43, 46, 78, 84). Due to the
limited disease development in immunocompetent mice, little is known about their host response
to H. hepaticus infection, and most of the published data relate to their use as control mice for
knockout studies.
Although H. hepaticus preferentially infects the cecal mucosa of mice and becomes a
dominant member of the microflora by 2 weeks post-inoculation (WPI) (38), infections in
immunocompetent hosts suggest both sex and strain differences with regards to both colonization
and host response. Analysis of cecal bacterial burden using quantitative PCR revealed higher
bacterial loads in male compared to female outbred Swiss Webster mice (31) and C57BL/6 mice
at 3 months post-inoculation (MPI) (15). However, in another study of C57BL/6 mice taken to 6
MPI there was not a gender difference in cecal bacterial load (86). This same study compared
so-called hepatitis-resistant C57BL/6 and hepatitis-susceptible A/JCr mice finding higher cecal
bacterial levels in the C57BL/6 mice (86). Cecum has the highest H. hepaticus burden, however
by qPCR H. hepaticus can be found in colon tissue of immunocompetent mice (31), but is rarely
quantifiable in livers of C57BL/6 mice (31). Although hepatitis-prone male A/JCr mice often
have elevated quantifiable liver burdens, and therefore, have been shown to have higher bacterial
numbers in their livers than female A/JCr mice (68).Liver and large intestinal histological
changes associated with H. hepaticus infection have mostly been reported in immunodeficient
mice and A/JCr hepatitis-susceptible mice. Liver lesions have been reported as early as 3MPI in
both male and female A/JCr mice (47). Similarly, no gender difference in hepatitis was found in
A/JCr mice after 6 months of infection (86). In contrast, liver involvement was not found in
C57BL/6 mice at 6 MPI (86). Cecal lesions in C57BL/6 and A/JCr mice have been evaluated as
early as 1 MPI, at which time neither C57BL/6 nor A/JCr mice had cecal disease (47).
Appearance of cecal lesions was reported at 3 MPI in both male and female A/JCr mice (47),
however another study found no typhlitis in either C57BL/6 or A/JCr mice at 6 MPI (86). By 12
MPI chronic typhlitis develops in A/JCr mice, but studies of other aged immunocompetent mice
are lacking, particularly C57BL/6 mice (88). As controls for immune knockout mice,
immunocompetent 129Sv/Ev and FVB mice were evaluated at 8 and 10 MPI, respectively, at
which times no cecal or colonic lesions were observed (18, 52).
Both innate and adaptive immune cells have been implicated in H. hepaticus disease
development. An early study found large intestinal lesions that were attributable to natural
infection with H. hepaticus in SCID and Nude mice of different strain backgrounds, which are
deficient in functional T and B cells (84). Further studies have gone on to characterize the
requirements for disease development in RAG1- or RAG2-deficient mice that also lack
functional T and B cells in addition to the contribution of different T cell subsets to pathogenesis
(8, 18, 19, 39-41, 53, 54).
H. hepaticus-induced disease in RAG-deficient mice varies in time-to-development
depending on the strain background with 129Sv/Ev RAG-deficient mice developing severe
typhlocolitis by 2 MPI, whereas few lesions were observed in C57BL/10 RAG-deficient mice
(18, 39, 54). This innate, T cell-independent intestinal disease involved increased numbers of
lamina propria leukocytes (LPL) with enrichment for neutrophils rather than monoyctes or NK
cells (54). Typhlocolitis in H. hepaticus infected 129Sv/Ev RAG-deficient mice was associated
with increased expression of cytokines IL-12/23p40, IL-23p19, IL-6, TNF-a, IP-10, IFN-y,
MCP-1, IL-1 , KC, IL-17 (18, 36). Treatment of H. hepaticus infected mice with anti-IL-
12/23p40 or TNF-a reduced disease pathology (54). Previously thought to be only a subunit of
IL-12, IL-12/23p40 subunit, the recent recognition that is shared with IL-23 lead to finding
increased IL-23 production with H. hepaticus-induced innate disease (36). When H. hepaticus
infected 129Sv/Ev RAG-deficient mice were treated with anti-IL-23p19 antibody, more dramatic
disease reduction was achieved than with anti-IL- 12/23p40 (36). Attenuated disease due to anti-
IL-23p19 treatment was accompanied by reduced colon cytokine expression, indicating IL-23
triggers a cascade of proinflammatory cytokines leading to development of innate disease (36).
Comparable reduction of H. hepaticus induced innate disease observed with anti-IL-23 treatment
is also found after addition of regulatory T cells to RAG-deficient infected mice (36, 40, 41, 53,
54).
Before Foxp3 was a well-established marker for naturally-occurring regulatory T cells
(nTreg), CD4* cells expressing low levels of CD45RB along with CD25
(CD4*CD45RBlowCD25*) were used as a regulatory T cell-containing subset of cells. Transfer
of these cells into 129Sv/EvRAG-deficient mice prior to H. hepaticus infection, ablated innate
intestinal disease development (18, 54). The influx of neutrophils in the lamina propria observed
with H. hepaticus infection was prevented with transfer of CD4*CD45RBlowCD25* regulatory T
cells, indicating that neutrophils are major contributors to cytokine production and disease
pathology. When 129Sv/EvRAG-deficient CD4*CD45RBlowCD25* transfer recipients infected
with H. hepaticus were treated with either anti-TGF-p or anti-IL-10R, the ability of the
transferred regulatory T cells to attenuate inflammation was prevented (54).
The important role of regulatory T cell populations in H. hepaticus induced disease was
further accentuated by their prevention of T cell-dependent disease. When either effector T cells
(CD4*CD45RBhigh) were transferred into 129Sv/EvRAG-deficient mice or CD4*IL-10-'- cells
were transferred into C57BL/10 RAG-deficient mice, H. hepaticus infection caused
typhlocolitis. Co-transfer of CD4+CD45RBlowCD25* cells inhibited H. hepaticus-induced
disease development in both models (41, 54). Similar to T cell-independent disease
administration of anti-IL-1OR antibodies prevented regulatory T cell suppression of T cell
dependent disease (41). The important role of IL-10 in H. hepaticus infection is highlighted by
the development of intestinal lesions from infection of either wild type C57BL/6 mice receiving
anti-IL-1OR antibody treatment or C57BL/6 IL-10-deficient or C57BL/10 IL-10-deficient mice
(8, 39-43, 64).
The IBD-like disease that develops in IL-10-deficient mice on either C57BL/6 or
C57BL/10 strain background occurs between 1 and 2 MPI. Cecal lesions are characterized by
epithelial hyperplasia, goblet cell loss, and moderate to severe inflammation with lymphocyte,
neutrophil and macrophage infiltration of the lamina propria. Mild to moderate inflammation of
the colon and rectum also occur, typically more severe in the proximal colon (8, 43).
Upregulation of MHC-II along with an influx of CD3+ cells in the colon is observed with
immunohistochemical staining (8, 42). Increased intestinal cytokine production or mRNA
expression of IL-17, IFN-y, TNF-a, IL-12/23p40, and iNOS have been found, compared to
uninfected IL-10-deficient control mice (42, 64). Intervention by cytokine depletion (anti-IL-
12 /23 p4 0 , anti-TNF-a, anti-IFN-y or double anti-TNF-a+anti-IFN-y antibody treatment) only
showed efficacy for anti-IL-12/23p40 (42, 43). H. hepaticus infected IL-10-deficient mice
treated with anti-IL-12/23p40 at 1 MPI for one month showed reduced cecal inflammation
consisting of fewer inflammatory infiltrates in the lamina propria and less epithelial hyperplasia
compared with control antibody treated mice (42,43). mRNA transcripts of IFN-y, TNF-a, and
iNOS were decreased in anti-IL-12 /2 3p4O treated mice, but not anti-TNF-a, anti-IFN-y or anti-
TNF-a + anti-IFN-y treated mice (42). Unlike IL-10/IFN-y double knockout mice that were still
susceptible to H. hepaticus intestinal disease, IL-10/IL-12/23p40 double knockout mice were
comparable to uninfected IL-12/23p40 and wild type C57BL/10 controls, indicating IL-12/23p40
plays a critical role in disease development (42).
Recently, the role of IL-10 signaling during H. hepaticus infection using anti-IL-10R
antibody treatment was used to dissect the roles of IL-12 versus IL-23 in H. hepaticus disease
development. Wild type C57BL/6 mice given anti-IL-1OR treatment develop comparable
disease to IL-10-deficient mice that can be blocked by co-administration with anti-IL-12p40
(40). Neither IL-12/23p40-deficient nor IL-12p35-deficient mice develop disease when infected
with H. hepaticus, however when treated with anti-IL-10R antibody, IL-12p35 mice develop
cecal and colonic disease comparable to wild type treated mice; indicating IL- 12 is not required
for H. hepaticus disease development. IFN-y has a minor role in disease development, as IFN-y-
deficient mice only develop comparable typhlitis, not colitis when treated with anti-IL-1OR
antibody (40).
Despite robust immune activation demonstrated by immunopathology and tissue
cytokines in immunodeficient mice, very little evidence of immune activation in
immunocompetent mice, particularly disease-resistant C57BL/6 mice, exists. Although the
immune system appears to be ignorant of H. hepaticus in wild type C57BL/6 mice, recognition
does occur, as serum H. hepaticus-specific immunoglobulin titers and fecal sIgA are detectable
(43, 87). Serum titers in C57BL/6 mice are even comparable to C57BL/6 IL-10-deficient (43).
Yet, there is little evidence for immune activation at the site of infection. Compared to IL-10-
deficient mice, MHC-II expression in the cecum and colon of wild type C57BL/6 mice was
minimal regardless of infection (8). Of many cytokines evaluated, only IL-17A (IL-17) had
increased expression in H. hepaticus infected C57BL/6 mice compared with uninfected mice
(40).
H. hepaticus is well adapted to persist in its natural host. Many knockout lines of mice
demonstrate the need for adaptive immunity in controlling mucosal inflammation and resulting
damage. Basis for these studies is the hypothesis that such adaptive immune responses in
subclinical persistent infection can influence the immune responses, either tolerogenic or
immunogenic, to oral tolerance to soluble antigen, protective immunity from immunization or
prior infection, and concurrent acute enteric infection.
Chapter 2
Helicobacter hepaticus causes persistent subclinical infection in
C57BL/6 mice
Megan E. McBee', Patricia Z. Zheng', Hilda Holcombe2 , Elizabeth B. Groff2,
Kathryn A. Schlieper 2, David B. Schauer1' 2
'Department of Biological Engineering; Massachusetts Institute of Technology; Cambridge,
Massachusetts, 02139, USA
2 Division of Comparative Medicine; Massachusetts Institute of Technology; Cambridge,
Massachusetts, 02139, USA
Introduction
Similar to the human pathogen Helicobacter pylori, H. hepaticus is highly prevalent in its
natural host: mice. Although eliminated from most commercial vendors, H. hepaticus is
enzootic in many academic research facilities. Additionally, H. hepaticus infection, like H.
pylori in humans, is life-long and subclinical. For H. hepaticus, the exception is susceptible
immunocompetent strains (A/JCr) in which it causes typhlocolitis, hepatitis, and liver cancer (24,
28, 37, 69, 85, 86). Both of these Helicobacter infections have been suggested to act through
similar mechanisms to remain subclinical, which is via careful regulation of host-microbe
interactions via regulatory T cells (16, 48, 65). Further evidence of this mechanism is that in
several strains of knockout mice, particularly those lacking adaptive immune functions, an
inflammatory bowel disease-like (IBD-like) condition develops (8, 9, 36, 39, 40, 42, 43, 46, 84).
If IL- 10 competent T cells are transferred into infected mice of an IBD-prone strain, the
proinflammatory events initiated by the H. hepaticus infection are contained, whereas cells
deficient in IL-10 have no effect on H. hepaticus-induced disease (18, 19, 41, 53). Since H.
hepaticus infection is most commonly studied in immune-deficient strains of mice, H. hepaticus
infected C57BL/6 mice were followed over time to determine whether disease progressed due to
alteration in immune regulation. Therefore, whether C57BL/6 mice have subclinical H.
hepaticus infection both histologically and immunologically after 2 or 18 months of infection
was determined.
Results
C57BL/6 mice infected with H. hepaticus show no weight change after 3 months of infection
Infection of male and female immunocompetent C57BL/6 mice with H. hepaticus for 2 to
3 months has not been previously characterized. Studies of shorter duration (1 month) (40) and
longer duration (6 months) (86) using H. hepaticus inoculated C57BL/6 mice as controls have
been reported. Between 2 and 3 months post-inoculation (MPI) H. hepaticus had no effect on
weight, as weight gain in infected mice was not significantly different from uninoculated
controls (Chapter 5, Figure 1 A). Establishment of infection in these mice was confirmed with
all-Helicobacter PCR on feces (data not shown). To verify that the immune system did in fact
respond to infection with H. hepaticus, antibody titers were measured.
H. hepaticus-infected mice make an H. hepaticus-specific serum IgG1 and IgG2c response
that is sustained for at least 11 weeks post-inoculation
Mice infected with H. hepaticus mount an adaptive immune response to H. hepaticus
antigens, including serum IgG, Thi, and Th17 cell populations (40, 43, 87). To confirm that the
adaptive response to H. hepaticus was present and comparable throughout the duration of
infection, the serum IgG1 and IgG2c response against H. hepaticus was monitored at 3, 8, and 11
weeks post-inoculation (WPI) as well as 18 months post-inoculation (MPI) in wild type
C57BL/6 and 8 WPI in C57BL/6 IL-10-deficient mice. H. hepaticus-specific IgG1 and IgG2c
titers were detectable by 3 WPI (data not shown). Titers increased between 3 and 8 WPI, but had
stabilized by 8WPI, as titers for both IgG 1 and IgG2c were comparable between 8 and 11 WPI
(Figure 2-1). IgG2c titers specific to H. hepaticus were comparable between IL-10-deficient and
wild type mice at 8 WPI, however IL-10-deficient mice had lower H. hepaticus-specific IgG1
titers than wild type mice, P <0.05 (Figure 2-1). These titers were not normalized to total
isotype in the serum, and if normalized, may not be significantly different. At 18 MPI H.
hepaticus-specific titers remain detectable (Figure 2-8) and normalized titers were not different
from 2 to 3 MPI (Chapter 5). Additionally, H. hepaticus-specific sIgA titers of between 0.1 and
1% of total sIgA in cecal contents were measured after 8 weeks of infection (Chapter 5).
Infection with H. hepaticus does not cause cecal or colonic lesions in C57BL/6 mice
As expected in wild type C57BL/6 mice, infection with H. hepaticus for up to 11 weeks
did result in cecal or colonic lesions (Chapter 3 and Chapter 5). The median colonic disease
index from mice infected with only H. hepaticus for 11 weeks was 0.25 with a range of [0.00-
1.00] compared with 0.0 (0.0-0.0) in uninoculated mice, P > 0.05 (from Chapter 5 experiment).
In these same mice, cecal disease was also not significantly different (1.0 [0.5-2.0]) compared
with 1.75 [0.50-2.00] in uninoculated mice, P > 0.05. After 18 months of infection C57BL/6
mice did not exhibit appreciable colonic or cecal lesions compared with age-matched
uninoculated mice, P > 0.05 (Figure 2-2). In contrast, marked cecal disease was present in A/J
mice at 18 MPI, P > 0.001 (Figure 2-2).
H. hepaticus infection increases IL-17 expression in the cecum, but other cytokines were
unchanged in cecum, colon or mesenteric lymph node
After 2 to 3 months of infection with H. hepaticus, cytokine mRNA expression in the
mesenteric lymph node (MLN) was not different from uninoculated mice (Figure 2-3).
Similarly, in distal colon tissue neither proinflammatory nor anti-inflammatory cytokine message
levels were distinguishable from uninoculated control mice despite the colon being a tissue
infected with H. hepaticus, P > 0.05 (Figure 2-4). The lack of change in cytokine mRNA
expression in either MLN or colon tissue substantiate the subclinical nature of H. hepaticus
infection. Since the cecum is thought to be the primary niche for H. hepaticus, cecal cytokine
expression was also evaluated. At 2 to 3 MPI, cecal expression of IL-6, TNF-a, IL-1 s3, MCP- 1,
IFN-y, IL-17, IL-12/23p40, IL-10, TGF-p, and Foxp3 were compared to uninoculated mice. The
only cytokine with differential expression in the cecum was IL-17, which was -10-fold higher
than uninoculated age-matched mice, P < 0.05 (Figure 2-5). As no lesions were apparent,
despite elevated IL-17 expression, the presence of Foxp3* regulatory T cells in the local tissue
was also assessed.
H. hepaticus infection does not increase local tissue Foxp3* cells
Several studies have implicated the involvement of multiple, and not mutually exclusive
regulatory T cell populations in H. hepaticus infection (14, 41, 53). However staining of cecum
and colon for the transcription factor Foxp3, which is commonly used as a marker for naturally-
occurring regulatory T cells, revealed no significant increase in Foxp3* cells in either cecum
distal colon after infection with H. hepaticus for 2 to 3 months (Chapter 5, Figure 5-4 and 5-9).
This does not rule out changes in the populations of other regulatory T cells for which there are
no exclusive markers, particularly IL-10 expressing TOl cells, thought to play a role in
containing clinical H. hepaticus disease (41).
Cecal cytokine expression does not change after 18 months of H. hepaticus infection in
C57BL/6 mice
Cecal cytokine expression after infection with H. hepaticus for 18 months was measured
to verify whether the tissue responses to infection remained unaltered. Although IL-17 had
increased expression after 2 to 3 months, it was not evaluated at 18 MPI. Cytokine measured
include innate cytokines (IL-6 and TNF-a) known to be important in H. hepaticus infection of
immunocompromised mice, anti-inflammatory cytokines (IL-10 and TGF-p) and Foxp3. At 18
MPI, innate cytokines were unchanged compared to age-matched uninoculated mice, 3- to 4-
month old uninoculated mice, and 3- to 4-month old mice infected with H. hepaticus for 2
months, P > 0.05 (Figure 2-6). Similarly, the anti-inflammatory cytokines and Foxp3 expression
were also unaltered, P > 0.05 (Figure 2-6). Since C57BL/6 mice have been shown have lower
susceptibility to H. hepaticus-induced disease compared with A/JCr mice, cytokine expression
was measured in cecums of age-matched A/J mice with and without H. hepaticus.
A/J mice have higher basal expression of cytokines at old-age than C57BL/6 mice, which
decrease with H. hepaticus infection
Comparison of cecal cytokines and Foxp3 from age-matched C57BL/6 and A/J mice not
inoculated with H. hepaticus showed strain-specific differences in which aged A/J mice had
higher basal expression of IL-6, TNF-a, TGF-6, IL-10, and Foxp3 (Figure 2-7). However, H.
hepaticus infected (18 MPI) A/J mice consistently had lower expression of all 5 transcripts than
uninoculated A/J mice, P <0.01 (Figure 2-7). When mice infected with H. hepaticus for 18
months from each strain were compared, A/J mice had increased levels of TNF-a, P <0.05
(Figure 2-7). Whether strain differences in host response to H. hepaticus were also detectable in
adaptive immunity, serum antibody titers were measured.
A/J and C57BL/6 mice show strain differences in H. hepaticus-specific IgG2a/c titers
To determine whether a change in the adaptive immune response to H. hepaticus is
partially responsible for differences in strain susceptibility to H. hepaticus induced disease late
during infection (18 MPI), serum immunoglobulin titers were measured. There was no
difference in IgG 1 titers specific to H. hepaticus between A/J and C57BL/6 mice 18 months after
infection (Figure 2-8). A/J and C57BL/6 mice express different Thl- dependent isotypes of IgG
(IgG2a and IgG2c, respectively), therefore their respective titers were measured and when
compared, H. hepaticus-specific titers in A/J mice (normalized to total IgG2a) was over and
order-of-magnitude higher than H. hepaticus-specific IgG2c in C57BL/6 mice, P <0.001 (Figure
2-8). Since H. hepaticus liver disease in A/J can be sex-specific, antibody titers were separated
into male and female mice (47, 86). No difference was observed between male and female mice
in either C57BL/6 or A/J mice.
Discussion
Many aspects of host response to infectious agents were evaluated in C57BL/6 mice at
early and late time points post-inoculation with H. hepaticus. Together, these studies confirm
that H. hepaticus infection in C57BL/6 mice is completely subclinical. C57BL/6 mice make a
specific immune response to H. hepaticus, as both IgGI and IgG2c titers were detectable as early
as 3 WPI through 18 MPI. However, not only was there an absence of intestinal lesions with
scores not significantly different from uninoculated Helicobacter-free control mice, but cytokine
expression remained unchanged out to 18 MPI, indicating the host and pathogen have adapted to
prevent host damage while maintaining a niche for H. hepaticus to survive.
An initial study comparing aged disease-susceptible A/J and disease-resistant C57BL/6
mice indicate strain differences with regard to immune response at the tissue level exist. Lower
expression levels of cytokines in H. hepaticus infected versus uninoculated A/J mice may
indicate an adaptive host response to attempt to limit immune responses without respect to
function. Additionally, other proinflammatory cytokines, such as IFN-y, not measured in this
study, could be preferentially increased. Although this study did not give conclusive results,
they are suggestive that further studies into strain differences in immune responses to H.
hepaticus would be worthwhile. Overall, these studies show that infection of C57BL/6 mice
with H. hepaticus is subclincal and remains subclinical throughout the life of the animal.
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Figure 2-1. H. hepaticus-specific IgG1 and IgG2c antibodies are generated as a result of H.
hepaticus infection. C57BL/6 mice persistently infected with H. hepaticus generated both IgG1
and IgG2c anti-H. hepaticus titers that were equivalent between 8 WPI and 11WPI. C57BL/6
IL-10-'- mice had lower IgG1 titers (not normalized) than C57BL/6 mice at 8 WPI, but H.
hepaticus-specific IgG2c titers were comparable. One-way ANOVA with Bonferroni post-test; *
P < 0.05.
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Figure 2-2. C57BL/6 mice infected with H. hepaticus for 18 months do not develop colonic
or cecal disease. Colonic disease was not present in C57BL/6 mice infected with H. hepaticus
for 18 months. Substantial colonic disease was also not present in H. hepaticus infected A/J
mice after 18 months of infection. A few C57BL/6 mice had minimal cecal lesions, however
they were comparable to uninoculated age-matched C57BL/6 mice, P > 0.05. In contrast A/J
mice infected with H. hepaticus for 18 months had mild to moderate cecal lesions with overall
markedly worse cecal disease, P <0.001. Kruskal-Wallis with Dunn's post-test; * P < 0.05, **
P <0.01, *** P <0.001.
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Figure 2-3. MLN cytokine expression in C57BL/6 mice did not change after 2 months post-
infection with H. hepaticus. Innate, pro-inflammatory, and anti-inflammatory cytokine
expression in the MLN of H. hepaticus infected C57BL/6 mice was indistinguishable from age-
matched uninoculated mice. Unpaired, two-tailed t test with Welch's correction when necessary;
P < 0.05 was considered significant.
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Figure 2-4. Colonic cytokine mRNA expression exhibit tremendous biological variation in
H. hepaticus infected and uninoculated mice, as such no differences were found. Young (3
to 4 months old) Helicobacter-free mice had over two orders of magnitude difference in colonic
cytokine expression levels. After 2-3 months of H. hepaticus infection, no changes in colonic
cytokines were found. Unpaired, two-tailed t test with Welch's correction when necessary; P <
0.05 was considered significant.
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Figure 2-5. Cecal cytokine expression in H. hepaticus infected C57BL/6 mice was
comparable to uninoculated counterparts, with a modest increase in IL-17 expression at 2
months post-infection. Most pro- and anti-inflammatory cytokine expression levels measured
were similar, regardless of H. hepaticus infection. IL-17 was the only cytokine with elevated
expression in H. hepaticus mice. Unpaired, two-tailed t test with Welch's correction; *P < 0.05.
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Figure 2-6. No change in cecal cytokine expression was observed in H. hepaticus infected
C57BL/6 mice between 2 MPI and 18 MPI. Cytokines produced by the innate immune system
(IL-6 and TNF-a) were not different between cecums of uninoculated and H. hepaticus infected
mice at 18 MPI. Cecal expression of regulatory T cell-associated genes (IL-10, TGF-s, and
Foxp3) was comparable between uninoculated and H. hepaticus infected mice at 18 MPI. No
temporal change in cecal expression levels of IL-6, TNF-a, IL-10, TGF-P, or Foxp3 was
observed between 2 MPI and 18 MPI. One-way ANOVA with Bonferroni post-test; P < 0.05
was considered significant.
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Figure 2-7. Expression of cecal cytokines was consistently elevated in A/J mice over
C57BL/6 mice in both uninoculated and H. hepaticus infected. Basal cecal IL-6, TNF-a, IL-
10, and Foxp3 expression was increased in uninoculated A/J over uninoculated C57BU6 mice
(IL-6 P <0.01; TNF-a P <0.001; IL-0 P <0.001; Foxp3 P <0.001). H. hepaticus infected
C57BL/6 mice had no change in cecal cytokine expression after 18 months of infection.
Compared with uninoculated A/J mice infected A/J mice had lower cecal expression of all
cytokines measured (P <0.01, except Foxp3 P <0.001). Among infected mice of both strains,
only cecal TNF-a expression was different with higher expression in A/J mice (P < 0.05). One-
way ANOVA with Bonferroni post-test.
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Figure 2-8. At 18 MPI H. hepaticus-specific IgG1 and IgG2a/c titers are comparable
between males and females of both A/J and C57BL/6 mice, but IgG2c titers in C57BL/6
mice are lower than IgG2a titers in A/J mice. As a percentage of total IgGI H. hepaticus
specific titers were equivalent between males and females of both A/J and C57BL/6 strains of
mice 18 MPI. Titers of the Thl-dependent isotype IgG2a/c were strain dependent as A/J mice
produce higher H. hepaticus-specific IgG2a than H. hepaticus-specific IgG2c in C57BL/6 mice.
One-way ANOVA with Bonferroni post-test; ** P < 0.01, *** P < 0.001 (compared with
corresponding group in C57BL/6 mice).
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Introduction
Antigen can engender tolerance or immunity, the outcome of which can be determined by
the presence of an adjuvant. When presented to the immune system in the context of an
adjuvant, antigen exposure results in antigen-specific immunity. Conversely, tolerance or non-
responsiveness to the antigen develops when no adjuvant is present during antigen presentation.
In addition, immunity depends on the route and site of exposure in terms of the type and
magnitude of the resultant immune response. Unlike parenteral antigen immunization in the
presence of an adjuvant, which typically elicits a strong immunogenic response, oral
immunization of antigen may lead to different responses depending on the presence of adjuvant,
including: local secretory IgA (sIgA) production in the mucosa, systemic priming with
production of serum antibodies and cell-mediated immunity, or systemic or local non-
responsiveness to the antigen upon subsequent encounter (21). Although immunity (humoral
and cell-mediated responses) develops for most mucosal infections, a robust adaptive immune
response against commensal microbiota and food antigen is not desirable. The normal gut is
remarkably adept at limiting immune responses to such antigens. Therefore, development of
mucosal non-responsiveness either via tolerance or ignorance to external non-self antigens,
which gain access via a natural route (orally) under physiological conditions (non-inflammatory),
is beneficial to the host. Consequently, specific suppression of cellular or humoral immune
responses to an antigen previously delivered by the oral route is a natural immunologic event
termed "oral tolerance" (21).
Current dogma suggests that the mechanism behind oral tolerance induction depends on
the feeding dose and duration employed. At least two mechanisms exist for oral tolerance,
which are not mutually exclusive. High-dose feeding protocols are thought to lead to clonal
deletion or anergy of antigen-specific CD4* T cells (12, 21, 29, 56, 76). While low-dose
continuous feeding protocols have been shown to generate regulatory T cells that mediate
suppression of antigen-specific CD4* T cells via cell-cell contact or secretion of suppressive
cytokines TGF-P and IL-10 (20, 22, 59, 95). However, well-controlled comparisons of feeding
protocols have not been published, and the same feeding protocol may, in fact, induce multiple
mechanisms of oral tolerance (21, 56).
Oral delivery of the same antigen that induces oral tolerance, when co-delivered with an
adjuvant leads to immunity. Hence, whether incidental enteric infection can act as an adjuvant
producing immunity instead of tolerance was investigated. Previous studies by Nagler-Anderson
et al. have demonstrated prevention of oral tolerance induction due to infection with the helminth
Heligsomoides polygyrus (71). The proposed mechanism is via a Th2-polarized adjuvant effect
as a result of the Th2-biased infection. This infection adjuvanticity was mediated through up-
regulation of co-stimulatory molecules on local antigen presenting cells (APC) (72).
To determine whether an immunomodulatory effect of subclinical persistent infection
with H. hepaticus alters systemic tolerogenic responses to orally delivered antigen, H. hepaticus
infected C57BL/6 mice were fed a single high dose of ovalbumin (OVA) or PBS as a control,
then subjected to peripheral immunization with OVA in Complete Freud's Adjuvant (CFA).
Additionally, it was determined whether H. hepaticus infection would prevent oral tolerance
induced via continuous feeding of high doses of antigen (1% OVA in drinking water). In
Helicobacter-free C57BL/6 mice, both feeding doses resulted in tolerance induction, although
continuous feeding was more efficient at reducing the peripheral recall response to OVA.
Persistent H. hepaticus infection in PBS-fed mice resulted in a modest reduction of OVA-
specific recall responses in both experiments. H. hepaticus infection affected the outcome of
single high-dose feeding by preventing tolerance induction, but not with continuous antigen
feeding. Induction of oral tolerance in mice lacking IL-10 was evaluated since regulatory T cells
have been implicated in oral tolerance induction specifically with continuous feeding regimens
(20, 23, 59, 73). Oral tolerance via either a single or continuous feeding of a high dose of OVA
in C57BL/6 mice is IL-10 independent.
Results
Modest oral tolerance induction in C57BL/6 mice when soluble antigen delivered via a
single high dose
Oral tolerance via a single 25mg oral dose of OVA has been demonstrated in BALB/c
mice (70-72). The feasibility of oral tolerance induction in C57BL/6 mice using the same
method of administration was evaluated. One week after feeding, mice were immunized with
OVA in CFA. Three weeks after immunization, cells from the draining popliteal and inguinal
lymph nodes (PLN) were re-stimulated with OVA in vitro to measure the magnitude of response
via production of cytokines. PLN of Helicobacter-free mice re-stimulated with OVA produced
less IFN-y when fed a single high-dose of OVA than when fed PBS, P <0.001 (Figure 3-1 A).
In contrast to IFN-y, a Thl cytokine, IL-13, a Th2 cytokine, was low and not different between
feeding groups (Figure 3-1 B). In addition to cytokine secretion in a recall response, primary
evidence of oral tolerance in vivo was evaluated by production of OVA-specific antibodies after
immunization with OVA. In Helicobacter-free mice, OVA-specific IgG2c titers were reduced
when mice had been fed a single high dose of OVA compared with PBS fed mice, P <0.001
(Figure 3-2 A). No difference was observed in OVA-specific IgG1 titers, which were low
compared with IgG2c (Figure 3-2 B). Immunization with antigen using CFA as an adjuvant is
known to produce a robust Thl-biased immune response. Therefore, the order of magnitude
greater OVA-specific Thl-dependent cytokine production and serum IgG2c antibody titers were
anticipated. In similar regard, the previous studies in BALB/c mice used incomplete Freud's
adjuvant (IFA) to generate a Th2-biased immune response (2). Immunization after feeding
boosts the immune response allowing for easier detection of differences in OVA-specific titers.
Use of C57BL/6 mice, thought to be Th -prone, to investigate the effects of H. hepaticus
infection, also thought to be more Th -prone than Th2 , lead to use of CFA rather than IFA for an
adjuvant. With this caveat, in C57BL/6 mice single high-dose oral administration of OVA
partially, but not completely, prevents an immunogenic response to immunization with OVA in
CFA.
Persistent H. hepaticus infection in C57BL/6 mice prevents induction of oral tolerance via a
single high dose of soluble antigen
In comparison to Helicobacter-free PBS-fed mice, IFN-y production was consistently
lower in PLN cells from H. hepaticus infected PBS-fed mice (Figure 3-1 A). This is an
interesting, but as yet unexplained phenomenon. Although, immune responses in OVA-fed mice
were equivalent in Helicobacter-free and H. hepaticus infected mice, the effect of infection on
immune response to OVA in CFA influenced the interpretation of the results. Therefore, in
Helicobacter-free mice, OVA feeding suppressed subsequent immune responses to OVA. In
contrast, with H. hepaticus infection immune responses to OVA were primed by OVA feeding as
PLN IFN-y production from H. hepaticus infected OVA-fed mice was higher than PBS fed
counterparts, P < 0.01 (Figure 3-1 A). As shown in Figure 1 B, IL-13 production was not
different between treatment groups. In vivo evaluation of oral tolerance by OVA-specific serum
IgG2c antibody titers demonstrated that tolerance was not induced in H. hepaticus infected
OVA-fed mice, as titers in H. hepaticus infected mice fed OVA were comparable to those fed
PBS, P > 0.05, (Figure 3-2 A). As seen in uninfected mice, serum IgG1 titers specific to OVA
were not different between treatment groups (Figure 3-2 B).
Continuous delivery of high doses of antigen effectively induces oral tolerance
PLN cells from Helicobacter-free mice given OVA-free drinking water produced IFN-y
(4.32 +/- 0.14 ng/ml) upon re-stimulation in vitro (Figure 5 A). In contrast, continuous feeding
of 1% OVA drinking water were tolerized, as PLN cells from Helicobacter-free mice did not
produce IFN-y (0.03 +/- 0.03 ng/ml) when stimulated in vitro, P <0.001 (Figure 3-5 A). This
tolerogenic effect of OVA feeding on Th1 cytokine production did not production tolerance of
the Th2 cytokine IL-13 (Figure 3-5 B). In vivo measurement of oral tolerance through OVA-
specific IgG2c titers was also suppressed in mice that received 1% OVA water compared with
OVA-free drinking water, P < 0.01 (Figure 3-2 C). The Th2-dependent IgG1 OVA-specific titers
were not different between feeding groups (Figure 3-2 D). Since robust oral tolerance was
induced in C57BL/6 mice by continuous feeding of 1% OVA water, the effect of H. hepaticus
infection on induction of oral tolerance via this feeding regimen was assessed.
Persistent H. hepaticus infection does not prevent oral tolerance via continuous high dose
OVA feeding
In contrast to results from single high dose feeding, H. hepaticus infected mice
continuously fed a high dose of OVA did not produce IFN-y in re-stimulated PLN cells, P <
0.001 compared to H. hepaticus infected PBS-fed mice (Figure 3-5 A). Similar to Helicobacter-
free mice, no difference in OVA-specific production of IL-13 was found (Figure 3-5 B). The
OVA-specific serum IgG2c antibody response appeared tolerized in H. hepaticus infected OVA-
fed mice, however it was only statistically significant when compared with Helicobacter-free
PBS fed mice, P < 0.01, not with H. hepaticus infected PBS-fed mice, P > 0.05 (Figure 3-2 C).
Analogous to Helicobacter-free mice, OVA-specific IgG 1 titers were not tolerized in 1% OVA
fed H. hepaticus infected mice (Figure 3-2 D). Interestingly, H. hepaticus infection decreased
IFN-y production in PLN of drinking water mice, similar to the finding in H. hepaticus infected
PBS-fed controls in the single high dose tolerance studies, warranting further study into the
effects of H. hepaticus on systemic responses to parenteral immunization (Figure 3-5 A). A lack
of inflammation in the lower bowels of the mice in both feeding experiments was confirmed, as
it could be a mechanism by which H. hepaticus prevented oral tolerance induction and instead
primed the immune system for increased IFN-y production. Additionally, numbers of naturally-
occurring regulatory T cells, which express Foxp3, in the cecum and colon were assessed
because studies have suggested they play a role in continuous feeding oral tolerance.
Neither active inflammation nor tissue Foxp3* T cells were associated with induction or
prevention of oral tolerance via a single high-dose of OVA in wild type C57BL/6 mice
Histological evaluation of cecum and colon revealed tissue lesions, including
inflammation, in H. hepaticus infected mice were not significantly different from Helicobacter-
free mice (Table 3-1). Thus, H. hepaticus infection primed for a Th1 response to a single high
dose of orally administered OVA in the absence of a visible intestinal inflammatory response.
Whether a single high dose of OVA increased numbers of naturally-occurring regulatory T cells
(Foxp3* nT,,g) present in cecal or colon tissue was determined. Foxp3+ cell numbers were not
increased in local tissue of OVA fed (11 Foxp3* cells per mm 2 cecum and 2 Foxp3* cells per
mm 2 colon) compared with PBS fed Helicobacter-free mice (18 Foxp3* cells per mm 2 cecum and
2 Foxp3* cells per mm 2 colon, Figure 3-3 A). In PBS fed mice, H. hepaticus infection caused a
decrease in the number of cecal, but not colonic Foxp3* cells per mm2 tissue (6 and 3,
respectively). Compared with Helicobacter-free OVA fed mice, H. hepaticus infected mice had
a trend for increased cecal numbers of Foxp3* cells that was not significant, however no change
in colonic Foxp3* cell numbers were seen in single dose OVA fed H. hepaticus infected mice
(Figure 3-3 A). An increase in cecal Foxp3* cells was seen in H. hepaticus infected mice when
they were fed OVA, P < 0.05. Changes in cecal Foxp3*cells numbers, although significantly
different were not associated with either tolerance or infection. Since Foxp3 is not an exclusive
marker for all regulatory T cell subsets, such as IL-10 secreting induced regulatory T cells (Tr1),
the role of the suppressive cytokine IL-10 was evaluated.
Induction of oral tolerance via a single high dose of soluble antigen in IL-10-deficient mice
suggests IL-10 independent mechanism of oral tolerance
To evaluate the role of IL-10 in oral tolerance induced via a single high dose of OVA, a
pilot study was conducted in which C57BL/6 IL-10-deficient mice were fed either PBS or OVA.
Results of this study are preliminary, as group size was small and study was not repeated due to
limited availability of Helicobacter-free C57BL/6 IL-10-deficient mice. Most likely because of
technical reasons, IFN-y production was not detected in PLN cells from Helicobacter-free PBS
fed mice. However, in this pilot study, in vivo tolerance was evaluated, along with the effect of
H. hepaticus infection on oral tolerance induction. In Helicobacter-free mice, OVA feeding via a
single high dose did not result in a decrease of OVA-specific IgG2c or IgG1 (Figure 3-4 A and
B). However, there was a trend for lower IgG2c titers in the Helicobacter-free OVA-fed mice
compared with PBS-fed. Additionally, in contrast to wild type mice, IL-10-deficient mice
infected with H. hepaticus showed a trend for oral tolerance after OVA feeding (Figure 3-4 A).
Given the limited number of animals in this pilot study, the results suggest that a single high dose
of OVA does result in tolerance in C57BL/6 IL-10 deficient mice. Additionally, H. hepaticus
infection appeared to have no affect on tolerance induction.
Oral tolerance induced by continuous feeding of high doses of antigen does not depend on
IL-10
Continuous feeding of 1% OVA has been shown to induce regulatory T cells, therefore
induction of oral tolerance via this feeding protocol was attempted in C57BL/6 mice deficient in
IL-10 (23, 59). IL-10-deficient mice are known to develop spontaneous colitis after 2 months of
age on the C57BL/6 background, depending on microbiota status and facilities, therefore
histological evaluation of cecum and colon was conducted. At the time of evaluation, 3 months
of age, there were no consistent histological changes observed in either the cecum or colon of
Helicobacter-free mice (Table 3-1). In vitro OVA re-stimulation assays had inconsistent results
in repeated studies (data not shown) possibly due to high variation in Thl responses from the lack
of IL-10 or technical issues. However, in vitro antibody data were consistent. OVA-specific
IgG2c titers were tolerized in mice fed 1% OVA water compared with that received only
drinking water, P < 0.05 (Figure 3-4 C). Similar to studies in wild type mice, OVA-specific
IgGI titers in mice continuously fed 1% OVA were not significant (Figure 3-4 D). Since 1%
OVA in the drinking water induced oral tolerance in C57BL/6 IL-10 deficient mice, the ability of
H. hepaticus infection to prevent induction was evaluated.
H. hepaticus infected IL-10 deficient mice are orally tolerized to OVA given continuously at
a high dose
Infection of C57BL/6 IL-10 deficient mice with H. hepaticus has previously been shown
to result in typhlocolitis beginning around 2 months post-inoculation (43, 64). To reduce the
likelihood of typhlocolitis, all experiments in IL-10 deficient mice were shortened to only one
month of persistent H. hepaticus infection at the time of OVA feeding, which resulted in limited
mild to moderate cecal and colonic lesions in 2 of 9 mice (Table 3-1). Comparison of OVA-
specific IgG2c titers revealed tolerance induction in H. hepaticus infected mice fed 1% OVA
drinking water when compared with infected mice given OVA-free water (Figure 3-4 C) and no
difference in OVA-specific IgG1 titers (Figure 3-4 D).
Foxp3* cell numbers in cecum or colon of IL- 10-deficient mice were only affected by H.
hepaticus infection, not OVA feeding protocol
Induction of oral tolerance in Helicobacter-free C57BL/6 IL-10-deficient mice via a
single high dose of OVA was not mediated by an increase in numbers of naturally occurring
regulatory T cells (Foxp3*) in either the cecum or colon, P > 0.05 (Figure 3-3 B). Additionally,
oral tolerance induction by continuous high-dose feeding in IL-10-deficient mice did not change
the mucosal Foxp3* cell numbers (Figure 3-3 B). Several IL-10-deficient mice infected with H.
hepaticus had elevated numbers of Foxp3* cells giving the infected groups increased numbers of
Foxp3* cells in the cecum (Figure 3-3 B). However, only the single feeding groups were
different from each other (5 Foxp3* cells per mm2 cecum in Helicobacter-free and 22 Foxp3*
cells per mm 2 cecum in H. hepaticus infected, P <0.05). Similarly, colons of H. hepaticus
infected mice fed a single high dose had elevated Foxp3* cells compared with Helicobacter-free
counterparts, P < 0.05. Although, when compared to H. hepaticus-infected PBS fed mice there
was no significant differences in either cecum or colon.
Discussion
Oral tolerance is a means for the host to prevent undesirable immunogenic responses to
antigens in frequent contact with mucosal immune compartments. Using oral tolerance as a tool
to observe the effects of a persistent infection on the mucosal immune response has provided
evidence for modulation of the natural tolerogenic response by persistent enteric infection. H.
hepaticus was able to prevent induction of tolerogenic responses to a single high dose of OVA.
Upon a single feeding of 25mg of OVA to Helicobacter-free mice, Thl-dependent IFN-y recall
response to OVA in vitro was halved resulting in a modest tolerance induction. In contrast, this
recall response in H. hepaticus infected mice was not tolerized, instead the infection primed for
increased IFN-y production. In vivo antibody titers confirmed the prevention of tolerance
induction as H. hepaticus infected mice had comparable OVA-specific antibody titers regardless
of OVA feeding. These results indicate that the presence of a persistent enteric infection such as
H. hepaticus can potentiate the host's response of oral tolerance to an antigen when exposed
once at a high dose.
Dose and duration of exposure to an antigen can affect the mechanism of oral tolerance
induction, either anergy/clonal deletion or active suppression by one or multiple regulatory T cell
subsets (12, 21, 22, 29, 95). Therefore, the ability of H. hepaticus to prevent oral tolerance was
evaluated at a comparable high dose of OVA, but for a continuous 5-day duration. In contrast to
a single exposure to soluble oral antigen, continuous feeding of the antigen caused more robust
tolerance demonstrated by a complete inhibition of IFN-y production during in vitro recall
response, as well as suppression of OVA-specific antibodies. Tolerance induced by this feeding
protocol was not altered by H. hepaticus infection, indicating that continuous exposure to high
doses of soluble antigen leads to tolerogenic responses in spite of a persistent enteric infection.
Given the fact that H. hepaticus infection revealed different mechanism for bolus and
continuous feeding oral tolerance, the role of IL-10 in each was investigated. Single feeding was
only attempted once, and although in the one experiment the trend that oral tolerance can be
induced in IL-10-deficient mice did not reach significance. Tolerance to soluble OVA through
continuous feeding was also intact in IL-10-deficient mice. Although in studies using a different
model antigen and continuous low-dose feeding, similar results were found in IL-10-deficient
mice (33). With tolerance inducible in IL-10 deficient mice, whether Thi responses to H.
hepaticus infection affected tolerance be evaluated, particularly because IL-10 deficient mice
develop disease when infected with H. hepaticus.
Mice deficient in IL-10 also lack active suppression of immune responses, particularly
towards Thi cells, thereby any effect of this suppression during either tolerance induction or H.
hepaticus infection are negated. Since the single dose experiment was not repeated, conclusive
statements cannot be formed. However they suggest that IL- 10 may play a role in H. hepaticus
preventing oral tolerance via single exposure to a high dose of antigen because the in vivo
antibody response has a trend towards tolerance in the H. hepaticus OVA-fed mice. In this
model, IL-10 is likely involved in the host response to H. hepaticus instead of tolerance
induction, as tolerance was intact.
Continuous exposure of soluble OVA at a high dose resulted in immunologic tolerance
to OVA, even in IL-10-deficient mice infected with H. hepaticus. Although the duration of
infection in the experiment was shortened in order to decrease the likelihood of H. hepaticus
induced disease in IL-10 deficient mice, in one of two experiments half of the infected mice had
developed disease by 2 MPI. However, both studies showed comparable results even though
some mice exhibited active intestinal inflammation. Active inflammation creates an
environment in the mucosa that is amenable to immunogenic, not tolerogenic responses. Yet, in
IL-10-deficient mice infected with H. hepaticus a robust tolerogenic response resulted from
continuous antigen exposure. This finding is intriguing, but requires carefully controlled studies
that also examine the local mucosal responses in more detail.
Taken together, these studies support the notion that duration of exposure to a soluble
antigen does cause different immunologic responses that all lead to induction of the phenomenon
of oral tolerance. Additionally, in certain instances, such as a single high level of exposure to an
antigen, persistent enteric infection can interfere with the natural mucosal immune responses,
thereby preventing tolerance induction. Further studies characterizing the mucosal responses to
these different exposures, both antigen and infection, will aid in understanding the interplay
between host and pathogen with regard to tolerogenic versus immunogenic responses.
Tables and Figures
Table 3-1. Cecal and colonic lesions only developed in a few H. hepaticus infected IL-10-
deficient mice. H. hepaticus infection of C57BL/6 mice did not result in cecal or colonic
lesions. No Helicobacter-free IL-10-deficient mice had cecal or colonic lesions at 3-4 months of
age. Some IL-10-deficient
colonic lesions.
C57BL/6
Uninfected/PBS: Cecum
Colon
Uninfected/25mg OVA: Cecum
Colon
Uninfected/1% OVA: Cecum
Colon
H. hepaticus/PBS: Cecum
Colon
H. hepaticus/25mg OVA: Cecum
Colon
H. hepaticus/1% OVA: Cecum
Colon
C57BL/6 IL-10-'
Uninfected/PBS: Cecum
Colon
Uninfected/25mg OVA: Cecum
Colon
Uninfected/1% OVA: Cecum
Colon
H. hepaticus/PBS: Cecum
Colon
H. hepaticus/25mg OVA: Cecum
Colon
H. hepaticus/1% OVA: Cecum
Colon
mice infected with H. hepaticus for 2 months developed cecal and
Inflammation Edema
Epithelial
Defects Hyperplasia Dysplasia
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
N/A N/A N/A N/A N/A
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
N/A N/A N/A N/A N/A
Epithelial
Inflammation Edema Defects Hyperplasia Dysplasia
0 (0-0) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0 (0-0) 0 (0-0.5) 0 (0-0) 0 (0-0) 0 (0-0)
0(0-1.0) 0(0-0) 0 (0-0) 0(0-1.0) 0(0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0.5) 0 (0-0)
0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0)
0(0-2.0) 0(0-1.0) 0(0-1.0) 0(0-2.5) 0(0-0.5)
0(0-0) 0(0-0) 0(0-1.0) 0(0-2.0) 0(0-0)
0(0-3.0) 0(0-1.0) 0(0-1.0) 0(0-2.0) 0(0-0)
0 (0-2.5) 0 (0-1.0) 0 (0-2.0) 0 (0-2.0) 0 (0-0.5)
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Figure 3-1. A single high dose of ovalbumin reduced IFN-y production upon re-stimulation
of PLN from Helicobacter-free mice, but not H. hepaticus infected C57BL/6 mice. Cells of
the popliteal and inguinal lymph nodes (PLN) from Helicobacter-free mice fed PBS produced
IFN-y, but PLN from mice fed a single 25mg dose of OVA had decreased IFN-y production (A).
Infection with H. hepaticus reduced the IFN-y production by PLN from mice fed PBS.
Compared with H. hepaticus infected mice fed PBS, feeding of a single 25mg dose of OVA to H.
hepaticus infected mice resulted in increased IFN-y production. Regardless of H. hepaticus
infection, a single 25mg dose of OVA did not affect IL-13 production by PLN (B). One-way
ANOVA with Bonferroni post-test; ** P <0.01, *** P <0.001.
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Figure 3-2. Both single and continuous high-dose feeding of ovalbumin reduce OVA-
specific IgG2c serum titers after systemic ovalbumin immunization, but persistent H.
hepaticus infection prevents the titer reduction from single high-dose feeding. Systemic
OVA-specific IgG2c titers (A), but not IgG1 titers (B) were reduced in mice fed a single 25mg
dose of OVA, however when mice were persistently infected with H. hepaticus feeding of a
single 25mg dose of OVA did not result in decreased OVA-specific IgG2c titers. Continuous
feeding of 1% OVA water suppressed OVA-specific IgG2c titers (C), but not IgGI titers (D). H.
hepaticus infection had no affect on OVA-specific IgG2c or IgGI titers when mice were
continuously fed 1% OVA. One-way ANOVA with Bonferroni post-test; * P < 0.05, ** P <
0.01, *** P < 0.001.
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Figure 3-3. Neither H. hepaticus infection nor feeding of a single 25mg dose of OVA
changed the number of Foxp3* cells in cecum or colon of C57BL/6 mice, but IL-10-deficient
mice infected with H. hepaticus had an elevated number of Foxp3* cells in the cecum and
colon. Numbers of Foxp3* cells in the cecum and colon of C57BL/6 mice remained stable
regardless of OVA feeding or H. hepaticus infection in the colon, but not the cecum (A). A lack
of IL-10 did not increase the number of Foxp3* cells in cecum or colon, regardless of feeding
protocol (B). H. hepaticus infection in IL-10-deficient mice caused an increase in Foxp3* cells
in the cecum and colon (B). One-way ANOVA with Bonferroni post-test; * P <0.05.
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Figure 3-5. Continuous feeding of a high dose of ovalbumin reduced IFN-y production
upon re-stimulation of PLN from Helicobacter-free and H. hepaticus infected C57BL/6
mice. PLN from Helicobacter-free mice fed PBS produced IFN-y, but PLN from mice fed 1%
OVA water had decreased IFN-y production (A). Infection with H. hepaticus reduced the IFN-y
production by PLN from mice fed PBS. Compared with H. hepaticus infected mice fed PBS,
feeding of 1% OVA water to H. hepaticus infected mice also suppressed IFN-y production.
Regardless of H. hepaticus infection, feeding of 1% OVA water did not affect IL-13 production
by PLN (B). One-way ANOVA with Bonferroni post-test; *** P <0.001.
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Introduction
Children are at highest risk for acute diarrheal disease with an estimated 17% of mortality
in children under 5 years of age (7). Vaccines against some of the most common causes of
diarrhea have not been successfully developed, partly due to a lack of efficient induction of
mucosal immune responses. In the mucosa, typically the primary site of infection and disease,
an effective vaccine will induce secretion of high concentrations of pathogen-specific sIgA, IgM,
and IgG, along with mucosal cell-mediated immunity (35, 61). Engendering strong protective
humoral and cell-mediated responses at the desired mucosal site is not trivial. Induction of
protective immune responses to enteric pathogens usually requires mucosal vaccination, as it is
more efficient than parenteral immunization at inducing immune responses in the mucosa. Due
to the difficulty in producing mucosal vaccines, only a few (six as of 2005) mucosal vaccines
have been approved for use in the United States or elsewhere, including vaccines against enteric
infections with poliovirus, rotavirus, Salmonella typhi, and Vibrio cholerae (35, 61).
One strategy to improve mucosal vaccine efficacy is through alternative formulation or
administration route of antigens and adjuvants. Prime/boost strategies have been widely studied
for both parenteral and oral delivery as a method to increase cell-mediated responses (44, 91).
Parenteral priming with the antigen(s) of interest followed by boosting with the same antigen
with a different adjuvant allows for presentation of the same antigen to the immune system in
two different contexts, which can lead to synergistic effects on immunity (44, 91). Application
of this immunization strategy to oral vaccination decreases the tendency for oral non-
responsiveness through tolerance induction or ignorance, as well as enhancing the mucosal
immune response. This prime/boost strategy with oral vaccination may offer a solution to
overcome the barrier of decreased immunogenicity observed with many oral vaccines in
developing countries (45).
A possible, but as yet largely unstudied, reason for reduced oral vaccine efficacy is the
effects of persistent bacterial infection on vaccine efficacy (45). Establishing an animal model in
which both immunization efficacy to an enteric infection, along with the effects of a unrelated
persistent infection could be examined will help address the issue of reduced vaccine efficacy.
In such a model, biomarkers for efficacious vaccination during concurrent infection could be
defined, as well as how concurrent mucosal infection influences immunogenic responses to
unrelated pathogens. Compared with the number of pathogens to which humans are exposed, a
single persistent infection is reductionist, yet, it would provide a more realistic scenario than
current vaccine models potentially leading to improved oral vaccines for use in developing
countries.
The use of animal models to study vaccines or interventions for diarrheagenic E. coli
infections, a common enteric pathogen in developing countries, is difficult as there is a lack of an
appropriate mouse model. Recently, Citrobacter rodentium, a murine pathogen related to
enteropathogenic E. coli (EPEC), has proven useful for studying virulence and pathogenesis of
acute diarrheal disease through in vitro and in vivo studies. C. rodentium clinical disease is
similar, although not identical, to EPEC including loose stool progressing to diarrhea in
susceptible strains of mice with associated weight loss and poor body condition (34, 49, 51, 60).
Although C3H/HeJ and FVB strains of mice succumb to death from C. rodentium infection
within 2 weeks, little is known about disease with respect to immunology in these strains, partly
because of the high mortality (3, 82). Conversely, much more is known about the immunology
of C. rodentium infection in C57BL/6 mice, in which C. rodentium causes self-limiting cecal and
colonic disease including hyperplasia, edema, destruction of the epithelial barrier, and
inflammation. (34, 49, 51, 60) Without confounding factors, such as a compromised immune
system, C57BL/6 mice recover from C. rodentium infection around three weeks after acquisition.
(49, 60) Similar to EPEC infection in humans, mortality rates in C57BL/6 mice infected with C.
rodentium are much greater early in life. Susceptibility to infection and disease during
adulthood, makes C. rodentium a useful model for EPEC vaccination, since vaccine efficacy
study are typically conducted in adult populations. To date, only two studies have evaluated
protective immunity to C. rodentium. In one study using C3H/HeJ mice, three-dose intranasal or
subcutaneous immunization with purified protein antigen (Int280a) with or without adjuvant
followed by challenge with C. rodentium gave a 2-log protection from bacterial burden, at best,
with a decrease in wet colon weight 13-16 days post-challenge (32). In the same study,
protective immunity to C. rodentium was assessed with naive and convalescent C3H/HeJ mice
demonstrating that prior infection reduced bacterial loads and colon weight 11 days post-re-
challenge. The second study found that prior infection with C. rodentium caused clearance of a
subsequent C. rodentium within one week in both C57BL/6 pIgR-deficient mice (lack secretory
IgA and IgM) and C57BL/6 mice (81). The field of EPEC vaccines would be significantly
advanced by the development of an effective vaccination for C. rodentium, a mouse model for
EPEC, particularly if produced in the presence of a persistent infection.
To determine whether a persistent infection, such as H. hepaticus, affects the efficacy of
immunization against an acute pathogen, C. rodentium, an efficacious immunization method was
needed. As C. rodentium is a mucosal enteric pathogen, antibodies that cross the epithelial
barrier, such as sIgA and IgG, are key to the first line of protection. Although oral vaccines are
preferred for ease of delivery, they typically have poor efficacy compared with their
subcutaneous or intramuscular counterparts. To verify whether parenteral or mucosal
vaccination provides greater efficacy for C. rodentium immunization, two prime/boost
vaccination strategies were tested: one utilizing parenteral and oral vaccination (subcutaneous
[s.c.] prime followed by a three-dose oral boost) and one with only parenteral vaccination (s.c.
prime followed by a single s.c. boost). Initially, these two immunization strategies were
evaluated in Helicobacter-free mice to determine the effect on: 1) C. rodentium-specific
antibodies; 2) disease development; 3) weight loss; and 4) bacterial burden. Neither
immunization strategy provided enough protection to assess the effects of H. hepaticus infection,
therefore prior C. rodentium infection was evaluated and used as the benchmark for protective
immunity. Evaluation of the effects of a persistent infection on host response should include
determination of whether the persistent infection prevents development of natural immunity (via
recovery from prior infection). H. hepaticus infection did not affect the bacterial burden upon
re-challenge with C. rodentium. Therefore, no other effects of persistent H. hepaticus infection
observed, such as weight loss or colonic disease, since clinical disease associated with C.
rodentium is correlated with bacterial burden.
Results
Immunization against C. rodentium produced C. rodentium-specific serum IgG1 and IgG2c
Generation of pathogen-specific immunoglobulins provides the host with an early, yet
specific, line of defense against subsequent infection with the same pathogen. Therefore, for
most pathogens an efficacious vaccine must cause the host to generate pathogen-specific
immunoglobulins. C. rodentium-specific IgG1 and IgG2c in the serum accounted for 10% and
1%, respectively, of total immunoglobulin isotype when mice were immunized via subcutaneous
prime with alum as an adjuvant followed by three oral boosts with cholera toxin as an adjuvant
(s.c. prime/oral boost) (Figure 4-1 A and B). Immunization of mice with a subcutaneous dose of
C. rodentium homogenate in alum followed by a subcutaneous immunization with only
homogenate (s.c. prime/s.c. boost) of C. rodentium homogenate resulted in comparable C.
rodentium-specific titers (1% of total IgG2c and 10% of total IgG 1) at 4 weeks post-primary
immunization. Additionally, seroconversion between males and females within each group was
similar. As expected for pre-C. rodentium challenge antibody titers, IgG1 titers were higher than
IgG2c titers due to the Th2-biased adjuvants (alum and cholera toxin) used for both subcutaneous
and oral immunizations. Quantities of immunoglobulins that cross the mucosal barrier, as
opposed to serum titers, are believed to be of importance for mucosal pathogens, such as C.
rodentium, as initial defense occurs in the mucosa. Serum IgGs were measured as they are
known to be required for eradication of C. rodentium (6, 50, 74, 81). The role of secretory IgA
(sIgA), typically the most abundant immunoglobulin in the mucosa, is not clear, and could play a
role as it was not measured. Since serum IgG1 and IgG2c were equivalent between vaccination
groups, the efficacy of the immunizations was assessed via challenge with C. rodentium.
Subcutaneous prime/oral boost immunization reduced C. rodentium bacterial burden in
50% of mice
Upon challenge with C. rodentium, naive mice had bacterial burdens of 108 CFU/g feces
at 3 days post-inoculation (DPI) (Figure 4-2 A). By 6 DPI peak bacterial burdens of 109 CFU/g
feces were reached, and this burden was maintained through 14 DPI, the end of the experiment.
Mice that received the s.c. prime/s.c. boost immunization strategy were not protected from
infection, as they had comparable bacterial loads to naive mice (Figure 4-2 A). In the s.c.
prime/oral boost group the cage of male mice (M) had 10' CFU/g feces at 3 DPI, but shedding
continued to increase reaching 109 CFU/g feces by 9 DPI. However, the female mice (F) given
s.c. prime/oral boost immunization strategy were protected from sustained bacterial shedding
with C. rodentium burdens below the detection threshold (103 CFU/g feces) by 9 DPI despite
having 106 CFU/g feces at 3 DPI, P <0.001 (Figure 4-2 A). Given the variable responses to the
immunization strategies, weight was monitored for the duration of C. rodentium challenge.
Subcutaneous prime/oral boost immunization strategy reduced weight loss associated with
C. rodentium clinical disease
Weight loss, used as a measure of clinical disease, in naive mice challenged with C.
rodentium occurred through the end of the study at 14 DPI. Between 3 DPI and 14 DPI naYve
challenged mice lost 5% of their body weight compared with a 2% weight gain in mice
unchallenged vehicle controls (received adjuvant with PBS only) as well as unchallenged s.c.
prime/oral boost immunization controls, P <0.05 (Figure 4-2 B). Subcutaneous prime/s.c. boost
immunization did not prevent nor delay weight loss due to C. rodentium infection, as weight loss
in these immunized challenged mice was comparable to naive challenged mice (Figure 4-2 B).
Both males and females that received the s.c prime/oral boost immunizations were not protected
from weight loss attributable to C. rodentium infection; weight loss between 3 DPI and 14 DPI
(2%) was intermediate for both males and females and was not statistically significant from
naive challenged, s.c. prime/s.c. boost challenged, immunized unchallenged or vehicle
unchallenged mice (Figure 4-2 B). Histological evaluation of colon disease in challenged mice
was completed to determine the extent of protection provided by each immunization strategy.
Early clearance of C. rodentium is associated with reduced colonic disease
At 14 DPI, challenge of naive mice resulted in marked colon disease, represented by a
colon disease index median of 7.75 (5.0-10.5) (Figure 4-3). Immunization via s.c. prime/s.c.
boost did not protect mice from C. rodentium disease development (Figure 4-3). Colon disease
(8.5 [6.5-10.0]) comparable to naive challenged mice was also observed in the s.c. prime/oral
boost M group. However, the s.c. prime/oral boost F group was protected from disease
development (2.0 [0.0-3.51, P < 0.05) with only minimal lesions at 14 DPI, indicating
immunization with C. rodentium homogenate has the potential to protect mice from subsequent
infection.
The best vaccination efficacy was achieved with the subcutaneous prime/oral boost
immunization strategy, which protected 50% of the mice from challenge with C. rodentium. In
order to successfully evaluate the interaction of a persistent infection on vaccine efficacy,
consistent protection in Helicobacter-free mice is desired. However, the development of natural
protective immunity to C. rodentium with and without a persistent H. hepaticus infection will
give a baseline for an ideal vaccine.
Prior C. rodentium infection prevents infection upon re-challenge
Naive C57BL/6 mice challenged with C. rodentium had 107 CFU/g feces at 4 DPI that
reached a maximum shedding burden of 1.5 x 10 CFU/g feces at 8 DPI (Figure 4-4 A). C.
rodentium burden began to decline around 12 DPI as bacterial shedding had decreased to 108
CFU/g feces. Mice previously inoculated with C. rodentium six weeks earlier did not shed more
than 103 CFU/g feces upon re-challenge, P <0.01 (Figure 4-4 A). After peak burdens at 4 DPI,
four orders of magnitude below naive counterparts, the convalescent mice had no detectable
bacteria in their feces (<103 CFU/g feces in average) for the remainder of the study. To confirm
this protection from sustained infection, weight of individual mice was monitored throughout the
study.
Mice previously infected with C. rodentium have minimal weight loss that is rapidly re-
gained
After initial weight loss between re-challenge and day 4 convalescent mice rapidly re-
gained weight, weighing more than their body weight at the day of re-challenge until study end
(Figure 4-4 B). Whereas, naive mice lost comparable amounts of weight during the first four
days of challenge followed by sustained weight loss through 11 DPI, P < 0.01 (Figure 4-4 B).
To determine whether this protection from prolonged weight loss was a result of reduced colon
disease severity, the histological lesions were evaluated.
Colon disease was less severe in convalescent mice
Substantial colon disease with a median disease index of 9.0 (8.0-10.5) was found at 11
DPI in naive mice (Figure 4-5). In comparison, convalescent mice had minimal disease at 11
DPI with a disease index of 1.5 (0.0-4.0), P <0.001 (Figure 4-5). None of the lesions evaluated
(epithelial defects, inflammation, hyperplasia, edema, and dysplasia) was preferentially
decreased nor constituted the sole component of the disease index of convalescent mice.
Consistent generation of protective immunity to C. rodentium through prior infection provides a
baseline from which to evaluate whether persistent H. hepaticus infection disrupts its
development.
Using challenge of convalescent mice with C. rodentium as a model of protective
immunity, mice infected persistently with H. hepaticus or Helicobacter-free mice were evaluated
for development of protective immunity including bacterial burden, weight loss, and colon
disease.
Persistent H. hepaticus infection does not prevent the development of protective immunity
to C. rodentium
As primary infection controls for the second C. rodentium challenge, a group of mice
were left uninoculated during the first C. rodentium inoculation, then challenged along with the
convalescent mice. These C. rodentium naive mice had bacterial burdens lower throughout the
study than previous infections (peak burden of 108 CFU/g feces versus 109 CFU/g feces in other
studies) indicating the strain of C. rodentium used for the second challenge was not comparable
to other strains with regard to infectivity and resulting disease (Figure 4-6 A). Two strains were
utilized to count only C. rodentium from the second infection. Helicobacter-free mice re-
challenged with C. rodentium had more than two orders of magnitude lower bacterial shedding at
4 DPI followed by burdens below the threshold of detection (Figure 4-6 A). When mice had a
persistent H. hepaticus infection and recovered from primary C. rodentium infection upon re-
challenge they had comparable bacterial burdens (at the threshold of detection, 103 CFU/g feces)
and clearance as Helicobacter-free mice (Figure 4-6 A). As confirmation of protective
immunity, weight of individual mice was monitored.
Re-challenge strain of C. rodentium did not cause weight loss in naive mice
The C. rodentium strain used for re-challenge in this study did not cause weight loss in
mice naive to C. rodentium, regardless of Helicobacter status (Figure 4-6 B), thereby making
weight loss unusable as a readout. Throughout the 3 weeks of monitoring, weight of naive mice
challenged with C. rodentium was comparable to the primary challenge control mice, which had
cleared their infection from 4 weeks earlier. Consistent with no weight loss in the naive mice,
convalescent mice re-challenged with C. rodentium did not have the initial weight loss observed
in the pilot study. H. hepaticus persistently infected convalescent mice also had no weight loss
during the 3 weeks post-re-challenge. The lack of weight loss does not preclude colonic disease
development, therefore the pathogenicity of the re-challenge strain was evaluated by assessing
cecal and colonic lesions.
No cecal or colonic lesions were present 3 weeks after re-challenge
In agreement with causing no weight loss, histological evaluation revealed no significant
cecal or colonic lesions in naive mice 3 weeks after challenge with C. rodentium (Table 4-1)
even when persistently infected with H. hepaticus. Although the study was taken to 3 weeks
post-inoculation (WPI), naive mice inoculated with C. rodentium were expected to have
histological evidence of infection, as another study has shown (see Chapter 5, Figure 5-3 and
Figure 5-8). In fact, the cecum and colon appeared similar to the primary challenge control mice
inoculated with only the first C. rodentium strain 7 weeks earlier (Table 4-1). Convalescent mice
with or without a persistent H. hepaticus infection had no lesions from the re-challenge, as well.
The lack of pathogenicity from the re-challenge strain made proper evaluation of whether H.
hepaticus infection affects protection from C. rodentium disease development impossible.
However, another marker for activation of the immune response at the site of infection is an
influx of Foxp3* T cells; therefore, numbers of Foxp3* cells were counted in cecal and colon
tissue.
Foxp3* cell numbers were not different between infection groups in either cecum or colon
Numbers of Foxp3* cells in the cecum and colon of mice used as controls for the primary
C. rodentium challenge were considered basal numbers, as 7 weeks had past since inoculation.
Basal numbers of Foxp3* cells were 6 per mm2 of cecum and 4 per mm2 of colon (Helicobacter-
free mice inoculated with C. rodentium 7 weeks earlier). Persistent H. hepaticus infection did
not change these basal numbers (Figure 4-7 A and B). Based on another study (see Chapter 5,
Figure 5-4 and Figure 5-9) numbers of Foxp3' cells were not expected to change in cecum 3
WPI, however an increase in the colon was expected during active disease 3 WPI with numbers
close to 20-30 per mm 2 of colon. Consistent with histological evaluation, no increase in Foxp3*
cell numbers was observed in cecum or colon of naive mice at 3 WPI with the re-challenge
strain, indicating little to no local activation of the immune system. Persistent H. hepaticus
infection did not affect the Foxp3* cecal or colonic cell numbers at 3 weeks after C. rodentium
challenge with the re-challenge strain (Figure 4-7 A and B). Similarly, cecal and colonic
numbers of Foxp3* cells in convalescent mice with or without H. hepaticus were unchanged
from basal numbers (Figure 4-7 A and B). As a final readout of local immune activation, colonic
cytokine mRNA expression levels were measured.
No changes in colonic cytokine mRNA expression levels 3 weeks after inoculation with the
re-challenge strain of C. rodentium
In another study, the colonic cytokine expression was evaluated weekly for four weeks
after inoculation with C. rodentium and found significant changes in mRNA expression of both
pro- and anti-inflammatory cytokines at 3 WPI. Therefore, as a highly sensitive measurement of
immune activation in the colon after infection with C. rodentium, the colonic cytokine mRNA
expression levels were measured in all infection groups. As shown in Figure 4-8, comparison of
expression levels to Helicobacter-free mice used as controls for the primary C. rodentium
challenge 7 weeks earlier revealed no changes in any of the cytokines, regardless of Helicobacter
or Citrobacter status.
Discussion
Protection against infection by enteric pathogens can be induced by vaccination or by
recovery from infection. In order to evaluate the effects of a persistent intestinal infection on the
efficacy of a vaccine for an enteric diarrheal infection, an efficacious immunization method was
needed. Initially, two strategies were evaluated in Helicobacter-free mice because no successful
vaccination method has been reported to date. The subcutaneous prime/s.c. boost strategy to
immunize against C. rodentium was not successful as evaluated by outcome of challenge with C.
rodentium, despite serum immunoglobulins specific to C. rodentium. Subcutaneous prime/oral
boost has potential to be an efficacious vaccine against C. rodentium, as 5 of 10 mice cleared the
infection within a few days and had reduced disease. However this vaccination strategy needs
to be re-evaluated with a follow-up study. The lack of protection observed in mice with serum
IgGs after immunization is in contradiction to reports of protection provided by convalescent
serum, specifically IgGs. One possibility is that mucosal immunoglobulins were not secreted
into the mucosa in quantities large enough to provide protection. Alternatively, other IgG
isotypes not measured (IgG3 or IgG2b) may be of greater importance for protection. Previous
reports of immunization strategies using mouse models of EPEC infection have not been
successful at preventing infection or disease. However, anecdotal knowledge indicates mice
previously infected with C. rodentium did not develop disease or symptoms of infection upon re-
exposure, indicating mice do develop protective immunity to C. rodentium. Since immunization
against C. rodentium could not be consistently achieved, and other studies have shown evidence
of protective immunity to C. rodentium, prior infection with C. rodentium was evaluated as an
alternative model for assessing the effects of H. hepaticus infection on immunity to an unrelated
pathogen.
Prior infection with C. rodentium provided protective immunity to subsequent infections,
which was virtually sterilizing, as only an initial loss of weight, corresponding with bacterial
shedding, followed by minimal histological evidence of infection at two weeks after re-challenge
was observed. These results confirm the anecdotal evidence and two studies stating convalescent
mice were protected from high bacterial burdens (32, 81). Prior infection with a pathogen is a
natural way to develop immunity to subsequent disease and typically provides better protection
than immunization, although at the expense of disease-associated morbidity and mortality.
Therefore, altering the development of natural immunity with another unrelated pathogen would
be difficult, but could demonstrate the full extent of effects a concurrent infection might have on
a host's immune system.
Issues with the pathogenicity of the re-challenge strain of C. rodentium made a thorough
analysis of the effects of a persistent H. hepaticus infection on protective immunity to C.
rodentium difficult to interpret. The re-challenge strain (DBS 129) did not cause weight loss,
cecal or colon disease, increased numbers of Foxp3* cells in colon tissue, or increased cytokine
expression. Despite a lack of pathogenicity, the study did determine that H. hepaticus infection
did not affect protection from sustained bacterial burden. C. rodentium-induced disease and
subsequent morbidity is closely linked with bacterial burden and duration of high burden.
Therefore, in order for H. hepaticus to alter C. rodentium-induced disease, mice would need to
lose protection from re-infection. Since comparable bacterial burdens were observed, the lack of
effect on other disease parameters was uninformative. Persistent H. hepaticus infection did not
affect the protective immunity to C. rodentium generated by a prior infection.
Notably, this is the first set of controlled studies to evaluate: 1) immunization strategies
for C. rodentium, a mouse model of EPEC infection; 2) protective immunity to C. rodentium via
prior infection; and 3) effects of a persistent intestinal infection on development of protective
immunity. Together, these results provide a good baseline for future evaluation of vaccines for
C. rodentium or EPEC infection. It is possible that H. hepaticus infection could influence a
primary C. rodentium infection without altering protective immunity. Further study into the host
response, with emphasis on the immune function, to C. rodentium would assist in the
development of more efficient vaccines. Additionally, studying the modulation of host response
to C. rodentium, a robust elicitor of mucosal immunity, with H. hepaticus infection will provide
more information on cross-talk in mucosal immunity.
Tables and Fi2ures
Table 4-1. Re-challenge strain of C. rodentium did not cause cecal or colonic disease and
was unaffected by H. hepaticus infection. At 7 weeks post-C. rodentium infection mice had no
cecal or colonic disease (TSB/Cr/LB) and mice also persistently infected with H. hepaticus no
longer had cecal or colonic disease. Any cecal or colonic disease resulting from the re-challenge
strain of C. rodentium had subsided by 3 WPI, which was unchanged by persistent H. hepaticus
infection. Prior C. rodentium infection did not change the lack of cecal or colonic disease
resulting from the re-challenge strain even with a persistent H. hepaticus infection.
TSB/Cr/LB TSB/LB/Cr TSB/Cr/Cr Hh/Cr/LB Hh/LB/Cr Hh/Cr/Cr
Cecum 0.75 1.0 0.5 0.0 1.0 1.0
Disease (0.5-1.0) (0.0-1.5) (0.0-1.0) (0.0-1.0) (0.5-1.0) (0.0-1.0)
Index
Colon 0.25 0.5 0.0 0.0 0.0 0.0
Disease (0.0-1.5) (0.0-1.5) (0.0-1.0) (0.0-0.5) (0.0-1.0) (0.0-0.5)
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Figure 4-1. Immunization with C. rodentium sonicate generates C. rodentium-specific
circulating antibodies. Pre-challenge C. rodentium-specific IgG2c (A) and IgG 1 (B) serum
titers were comparable between s.c. prime/s.c. boost and all s.c. prime/oral boost groups of mice.
Gender did not affect pathogen-specific titer percentage of total isotype, shown for s.c.
prime/oral boost challenge group. One-way ANOVA with Bonferroni post-test; P <0.05 was
considered significant.
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Figure 4-2. Immunization did not consistently prevent or reduce bacterial burden or
weight loss during C. rodentium challenge. Fecal shedding of C. rodentium (A) in s.c.
prime/s.c. boost and s.c. prime/oral boost male groups were equivalent to unimmunized mice.
Subcutaneous prime/oral boost females cleared C. rodentium by 1 WPI. C. rodentium caused
weight loss (B) between 3 DPI and 14 DPI in unimmunized and s.c. prime/s.c. boost challenged
groups. Both males and females in the s.c. prime/oral boost group challenged with C. rodentium
lost weight by 14 DPI, however not as much other challenged groups. One-way ANOVA with
Bonferroni post-test, * P <0.05.
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Figure 4-3. Reduced colonic disease in mice with decreased bacterial burden. C. rodentium
challenge caused marked colon disease at 14 DPI in unimmunized mice. Only s.c. prime/oral
boost females did not develop comparable colon disease. Kruskal-Wallis with Dunn's post-test;
* P < 0.05.
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Figure 4-4. C. rodentium infection provides protection from re-infection and associated
weight loss. Fecal shedding of C. rodentium (A) was near the threshold of detection (103 CFU/g
feces) in mice previously infected with C. rodentium compared with greater than 6 logs higher
burdens in naive mice. Prior C. rodentium infection did not prevent an initial period of weight
loss (B), however convalescent mice gained weight afterwards compared with continued weight
loss in naive mice. Two-way ANOVA with Bonferroni post-tests; ** P <0.01, *** P < 0.001.
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Figure 4-5. Prior C. rodentium infection prevents colonic disease development. Nalve mice
challenged with C. rodentium develop intense colonic disease at 11 DPI. However, convalescent
mice had only minor colonic disease. Mann-Whitney with two-tailed t test; *** P < 0.001.
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Figure 4-6. Persistent H. hepaticus infection does not affect protection from decreased
bacterial burdens in convalescent mice. C. rodentium fecal shedding (A) was comparable in
each group inoculated with C. rodentium regardless of H. hepaticus infection. C. rodentium
infection associated weight loss (B) did not occur with the second challenge strain. Two-way
ANOVA with Bonferroni post-tests; P <0.05 was considered significant.
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Figure 4-7. No increases in cecal or colonic Foxp3* cell numbers were observed with C.
rodentium re-challenge despite persistent H. hepaticus infection. Mice persistently infected
with H. hepaticus and inoculated with C. rodentium 7 weeks earlier had no increase in cecal (A)
or colonic (B) Foxp3* cells. Regardless of Helicobacter status, the re-challenge strain of C.
rodentium caused no increase in cecal or colonic Foxp3* cells 3 WPI. Convalescent challenged
mice also had no change in cecal or colonic Foxp3* cells even with a persistent H. hepaticus
infection.
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Figure 4-8. Colonic mRNA cytokine expression was not altered by either H. hepaticus or C.
rodentium infection. Infection with H. hepaticus did not change pro-inflammatory or anti-
inflammatory cytokine mRNA expression 7 WPI (TSB/Cr/LB versus Hh/Cr/LB). No increase in
cytokine mRNA was observed upon challenge with the second strain of C. rodentium
(TSB/LB/Cr), nor did H. hepaticus affect the mRNA levels. No mRNA cytokine response to the
second challenge strain of C. rodentium was observed in convalescent mice regardless of
Helicobacter status.
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Chapter 5
Persistent subclinical Helicobacter hepaticus infection modulates host response
to Citrobacter rodentium causing prolonged disease
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Introduction
Diarrheal disease caused by enteropathogenic Escherichia coli (EPEC) is a major health
problem, particularly in developing countries where access to clean drinking water is limited.
The frequent occurrence of EPEC infections in developing countries where a large fraction of the
population also has a persistent infection, such as Helicobacterpylori, make a mouse model of
polymicrobial enteric infection useful for understanding the effects of persistent infection on
acute diarrheal disease. Recently, Citrobacter rodentium, a murine pathogen related to EPEC,
has proven useful for studying virulence and pathogenesis of acute diarrheal disease through in
vitro and in vivo studies. Similar to EPEC infection in humans, clinical disease in C57BL/6 mice
is characterized by loose stool progressing to diarrhea in severe cases, weight loss that can lead
to death, and poor overall body condition (34, 49, 51, 60). Histologically, C. rodentium infection
causes self-limiting cecal and colonic disease, including hyperplasia, edema, destruction of the
epithelial barrier, and inflammation, with variable degrees of severity depending on age at
infection and concurrent infection status, such helminthes (34,49, 51, 60). Without confounding
factors, such as a compromised immune system, mice recover from the infection four to six
weeks after inoculation (49, 60).
An estimated 50% of the world's population is infected with Helicobacterpylori, making
it among the most common bacterial pathogens (63). Left untreated, infections with H. pylori are
life-long and usually subclinical. In a small subset of people, complications develop, including
peptic ulcers and neoplasia (less than 3%) (63). Helicobacter hepaticus, a related murine
pathogen, serves as a good model of persistent enteric infection as it is also a life-long and
subclinical infection (24, 28, 37, 69, 85, 86). Additionally, similar mechanisms have been
suggested for both Helicobacter infections in that they remain subclinical through careful
regulation of host-microbe interactions via regulatory T cells (16, 48, 65). Studies in several
strains of knockout mice, particularly those deficient in adaptive immune functions, indicate the
host response to H. hepaticus includes regulation of the innate and adaptive immune responses
because an inflammatory bowel disease-like (IBD-like) condition develops in these strains of
mice when infected with H. hepaticus (8, 9, 36, 39, 40, 42,43, 46, 84). When IL-10 competent
T cells are transferred into infected mice, the proinflammatory events initiated by H. hepaticus
infection are contained (18, 19, 41, 53).
A novel mouse model of polymicrobial infection was developed to characterize the
immunomodulatory effects of persistent H. hepaticus infection on host response to the enteric
diarrheal pathogen C. rodentium in C57BL/6 mice. Understanding alterations in host response to
an acute infection attributable to concurrent persistent infection will be useful in developing a
model for acute diarrheal disease in populations at risk for underlying infections. By
characterizing clinical and immunological disease features throughout the course of the acute
infection, important factors affected by persistent infection during the short-term as well as long-
term can be determined.
Results
H. hepaticus prolongs clinical disease without affecting C. rodentium bacterial burden
In agreement with previous reports in C57BL/6 mice (50, 89, 90), C. rodentium bacterial
burden, based on fecal shedding reached a maximum of 109 CFU/g feces between 1 and 2 weeks
post-inoculation (WPI) (Figure 5-1 A). Clearance of C. rodentium occurred during the following
week, as fecal shedding fell to undetectable levels (<103 CFU/g feces) by 3 WPI. Persistent
infection with H. hepaticus had no significant effect on fecal shedding, P > 0.05 (Figure 5-1 A).
Recent studies (50, 89) have highlighted the cecum as a niche for C. rodentium early during
infection. Bacterial burden in the cecal contents of mice at 1 WPI was not different between
mice singly infected with C. rodentium (3 ± 5x10 7 CFU/g cecal content) and mice concurrently
infected with H. hepaticus (4± 2x10 7 CFU/g cecal contents). In addition to confirming
infection through bacterial burden, clinical disease was assessed by monitoring weight, since C.
rodentium causes fluid imbalance and weight loss (3).
In contrast to infection with only H. hepaticus, in which weight was comparable to
uninoculated mice, clinical weight loss due to C. rodentium was apparent within 1 WPI (Figure
5-1 B). C. rodentium-infected mice lost an average of 4% of their initial body weight by 12 days
post-inoculation (DPI), whereas uninoculated mice had no change in body weight, P <0.01.
Helicobacter-free mice regained lost weight and were comparable to uninoculated mice by 21
DPI, which is consistent with previous reports in C57BL/6 mice (83). Weight loss in mice
infected with H. hepaticus and inoculated with C. rodentium was comparable to Helicobacter-
free mice with C. rodentium through 18 DPI. However, concurrent H. hepaticus infection
limited weight gain, which became apparent at 3 WPI (P <0.01 compared to C. rodentium
singly-infected mice). Chronic impairment of weight gain was seen, as at 4 WPI the persistently
infected mice had lower body weight than uninoculated mice, P <0.001 (Figure 5-1 B). Given
the effects on clinical disease, both immune response directed against C. rodentium and tissue
lesions were evaluated.
C. rodentium-specific serum immunoglobulins are indistinguishable between H. hepaticus
infected and Helicobacter-free mice
Development of C. rodentium-specific immunity occurs during the first two weeks after
inoculation with specific immunoglobulins detectable after two weeks (5). C. rodentium-specific
immunoglobulins, particularly IgG isotypes are important for resolution of infection and
prevention of prolonged bacterial burden-associated disease, as failure to develop systemic C.
rodentium-specific IgGs leads to sustained infection, lesions, and increased mortality (5, 6, 50,
74). Three weeks post-C. rodentium inoculation, singly-infected mice had an average serum C.
rodentium-specific IgM titer of 80 [tg/ml or 5.2% of total serum IgM (Figure 5-2 C). The later-
developing C. rodentium-specific IgGs had lower serum titers of 6 [tg/ml or 0.7% of total IgG2c
and 6 tg/ml or 0.7% of total IgG1 (Figure 5-2 B). Secretion of C. rodentium-specific sIgA into
the cecal lumen had not occurred by 1 WPI, as no samples had detectable sIgA in C. rodentium-
specific ELISAs. Total sIgA in cecal contents of uninfected and C. rodentium-infected mice
were equivalent (347 pg/g cecal content and 383 [tg/g cecal content, respectively). At 3 WPI,
subclinical infection with H. hepaticus had no significant effect on the serum titers of C.
rodentium-specific IgM, IgG1, or IgG2c as shown in Figure 5-2 B and C. Cecal levels of total
sIgA in mice concurrently infected with H. hepaticus and C. rodentium were elevated in
comparison with all cohorts at 1 WPI, however the percentage of H. hepaticus-specific sIgA did
not differ significantly (Figure 5-2 C).
Persistent H. hepaticus infection prolongs C. rodentium-induced colonic disease
To determine whether persistent H. hepaticus infection caused alterations in colon
disease, the severity of lesions was assessed. Although H. hepaticus infection is used as a model
of IBD in immune knockout mice (8, 9, 43), the subclinical nature of H. hepaticus infection in
C57BL/6 mice was confirmed by the lack of colonic lesions in age-matched infected mice
(Figure 5-3 A and B). In contrast, colonic disease was apparent in C. rodentium-inoculated mice
by 1 WPI consisting of mild inflammation, edema, epithelial destruction, and hyperplasia with a
disease index of 4.0 (0.0-6.0) (Figure 5-3 A, P < 0.001 compared with uninoculated mice). Over
the following week, appreciable colonic disease developed reaching a maximal severity of 9.0
(7.0-12.0) (Figure 5-3 A and C). Disease resolved in Helicobacter-free mice during weeks 3 and
4 post-inoculation reaching 2.0 (0.5-4.5) at 4 WPI (Figure 5-3 A and E). Concurrent H.
hepaticus infection had no significant effect on maximal colonic disease development (Figure 5-
3 A and D) with the highest disease index, also occurring at 2 WPI, of 8.5 (5.5-10.0). However,
persistent H. hepaticus infection did prolong colon disease, as the disease index at 4 WPI was 4.5
(2.5-7.5) compared with 2.0 (0.5-4.0) in C. rodentium singly infected mice, P < 0.001 (Figure 5-
3 A, E, and F). Since Foxp3* regulatory T cells (nTeg) have been associated with active colitis
(79), and C. rodentium-inoculated mice persistently infected with H. hepaticus had delayed
weight gain and prolonged colitis, the colon was examined for nTeg cells.
Foxp3* nT,g accumulate in colon of C. rodentium-infected mice during active disease
Growing evidence of increased numbers of nT,,,g cells at the sites of active mucosal
disease (11, 65-67, 79), suggests the role of nTreg cells at these sites is to contain the immune
response. Therefore, to determine whether the delayed disease resolution was associated with an
increased regulatory immune response, Foxp3+ cells in the colon were counted. Single infection
with H. hepaticus caused no increase in numbers of colonic Foxp3* cells (Figure 5-4 A).
Similarly, early after C. rodentium inoculation (1 WPI) no significant increase in the number of
colonic Foxp3* cells was observed. However, once marked colonic disease developed, C.
rodentium-inoculated mice had an average of 10 and 21 Foxp3* cells/mm2 of colon at 2 and 3
WPI, respectively, compared with 1 Foxp3* cells/mm2 of colon in uninoculated mice (Figure 5-4
A and B, P <0.001). By 4 WPI, colonic numbers of Foxp3* cells in Helicobacter-free mice
were not significantly different from basal levels (Figure 5-4 A and D). Although accumulation
of nTreg cells occurred regardless of Helicobacter status at 2 and 3 WPI, increased numbers were
observed earlier (1 WPI) in mice concurrently infected with H. hepaticus (2 Foxp3* cells per
mm 2 in C. rodentium compared with 9 Foxp3* cells per mm2 in H. hepaticus with C. rodentium,
Figure 5-4 A). In striking contrast to a return to basal numbers in Helicobacter-free mice, at 4
WPI Foxp3* cells remained elevated in mice concurrently infected with H. hepaticus, P <0.001
(Figure 5-4 A and E). Increases in nT,, cell numbers during C. rodentium infection
corresponded to active disease, similar to the findings in humans (79), indicating the increased
presence of nTreg cells could be a marker for active disease and could play a role in containing
tissue damage. The colonic tissue cytokine expression profile was measured in order to
determine whether a different cytokine expression pattern was associated with the prolonged
colitis observed in mice with a persistent H. hepaticus infection.
C. rodentium induces colonic expression of both proinflammatory and anti-inflammatory
cytokines mirroring colonic disease severity
C. rodentium has been reported to be a Thl-inducing disease (6, 34, 75), however a recent
study gives strong evidence for a major role of IL-17, produced by Th 7 cells, in disease
development (55). Therefore, expression levels of cytokines and other factors thought to be
involved in mucosal inflammation or colon disease were measured to characterize the basis of
differences in clinical and pathological disease outcome. Two-way ANOVA revealed colonic
transcripts for TNF-a, IFN-y, IL-12p35, and IL-12/IL-23p40 (Figure 5-5), along with IL-6,
MCP-1, IL-1 s, Foxp3, and IL-10 (Figure 5-6) had maximal expression in colons of mice
infected with C. rodentium 2 WPI (P <0.001, except IL-6 P <0.05 compared with uninoculated
mice). Th2-associated cytokines IL-13 and IL-4 were not detected. With a few exceptions
colonic transcripts of all genes measured followed a similar expression pattern: increased
expression as disease became more severe, maximal expression at 2 WPI paralleling disease
severity, decreased expression during disease resolution, and a return to near basal expression by
4 WPI. In contrast to this general pattern, expression of MLCK and IL-23p19 did not change
over the course of infection, and IL-17 expression increased reaching a plateau at 3 WPI (Figure
5-5). In the study looking at IL-17 in C. rodentium infection (55), assessment was made at 8
DPI, and these results are in agreement as the current study does show higher colonic expression
of IL-17 than IFN-y at 1 WPI. Interestingly, when disease is evaluated for a longer duration, the
pronounced flux in Thl-associated cytokines confirms the dominant Th1 nature of C. rodentium-
induced colonic disease.
C. rodentium-induced disease correlates with Th1 proinflammatory cytokines
To determine whether type 1 cytokines were associated with acute disease pathogenesis,
correlation analysis of mRNA expression in individual mice and their disease index was
performed with all animals from all times post-inoculation, regardless of infection status. Acute
C. rodentium-induced disease correlated with colonic gene expression of Th1 proinflammatory
cytokines, but not with IL-17 (Figure 5-7). The analysis revealed a strong positive correlation
between maximal disease severity and Th1 cytokines TNF-a, IL-12p35, IL-12/23p40, and in
particular IFN-y (Spearman r = 0.763, P <0.0032). In contrast, neither IL-23p19 nor IL-17 were
significantly correlated with acute disease severity (IL-17: Spearman r = 0.097, P > 0.05). Since
cytokine expression was strongly correlated with disease, differences in expression during
persistent H. hepaticus infection were evaluated.
H. hepaticus infection modulates Thl-Thl 7 cytokine expression in colon of C. rodentium
infected mice
Comparison of C. rodentium-induced mRNA transcripts with or without concurrent H.
hepaticus infection revealed that H. hepaticus infection did not change the temporal colonic
cytokine expression pattern, except IL- 17, of which the expression level continued to increase
from 3 to 4 WPI. This profile is in contrast to equivalent expression between 3 and 4 WPI in C.
rodentium singly-infected mice (Figure 5-5). Two-way ANOVA revealed no significant
differences in C. rodentium-induced transcript levels at 1 WPI when mice were concurrently
infected with H. hepaticus (Figure 5-5). However, maximal expression levels of IFN-y and IL-
12p35, observed at 2 WPI, were lower (P < 0.05) in mice with a persistent H. hepaticus infection
indicating H. hepaticus infection suppresses the ThO response to C. rodentium. By 4 WPI, when
Thi cytokines were approaching basal expression (Figure 5-5), IL-17 transcript levels continued
to escalate in mice with a persistent H. hepaticus infection, reaching a 202-fold increase over
uninoculated mice. Compared with C. rodentium singly infected mice, persistent H. hepaticus
infection resulted in a modest increase in colonic IL- 17 expression at 4 WPI (2-fold, P < 0.05).
Overall, persistent infection with H. hepaticus modulates C. rodentium-induced cytokine
expression by both slightly suppressing levels of Th cytokines while allowing for a modest
enhancement IL-17 response late. Increased IL-17 expression during prolonged disease in
persistently infected mice, along with its association with chronic inflammation (93) and IBD
(30, 62), indicate chronic disease may be mediated via IL-17.
Modest cecal disease appears early during C. rodentium infection, but is prevented by
persistent H. hepaticus infection
Infection of the cecum by C. rodentium has been suggested as the initial site for
activation of host response and disease development (89). As the primary location for H.
hepaticus-induced cecal lesions, the ileocecolic junction evaluated for lesions. Additionally, the
cecal apices were often removed for mRNA expression and could not be assessed in those
studies. Compared to uninoculated mice (0.75 [0.0-1.5]), mice infected with C. rodentium
developed evident cecal disease by 1 WPI with a disease index of 4.25 (1.5-9.0), P <0.001
(Figure 5-8 A). During the second week after inoculation, disease was resolving (3.0 [0.5-5.5],
yet still worse than uninoculated mice, P < 0.001. By 3 WPI, disease had resolved as there was
no significant difference in overall cecal disease severity between uninoculated mice (1.5 [0.5-
2.0]) and C. rodentium singly infected mice (2.0 [1.5-2.5]). Imaging studies have shown an
initial accumulation of C. rodentium in the cecum near the cecal apex,(89) however, in an
experiment where the apex was not removed, comparable disease developed at both the apex and
ileocecolic junction at 1 WPI (Figure 5-8 B). In contrast to single infection with C. rodentium,
persistent H. hepaticus infection during C. rodentium infection prevented cecal disease; at all
time points, cecal disease was comparable to uninoculated mice and attenuated compared with
Helicobacter-free C. rodentium inoculated mice, P < 0.001 (Figure 5-8 A). However, in the
cecal apex the cecal disease seen in Helicobacter-free C. rodentium inoculated mice was
similarly observed in H. hepaticus-infected mice 1 week after C. rodentium inoculation, P > 0.05
(Figure 5-8 B). Since regulatory T cells could be responsible for differences in disease severity,
the numbers of Foxp3* nTreg were counted in cecal tissue.
No changes in numbers of Foxp3* cells occurs in the cecum when mice are infected with H.
hepaticus or C. rodentium
Cecal tissue was stained for Foxp3 expression to determine whether differences in C.
rodentium-induced cecal disease when mice were persistently infected with H. hepaticus was
associated with changes in tissue Foxp3* nT, r. Generally, basal levels of Foxp3 expressing cells
in the cecum were ~5-fold greater than basal colonic numbers. Compared with uninoculated
mice, which had between 5 and 10 Foxp3* cells per mm2 cecum at all time points, infection with
C. rodentium did not result in an accumulation of Foxp3* cells even when disease was present at
1 and 2 WPI, P > 0.05 (Figure 5-9). Additionally, mice also persistently infected with H.
hepaticus had no change in Foxp3* cells in the cecum (Figure 5-9). Given the strong induction
of colonic cytokines during peak colon disease, the cecal cytokines were measured to determine
whether similar expression occurred during cecal disease.
Cecal disease is associated with a shift in the balance of anti-inflammatory and
proinflammatory cytokines
Regardless of H. hepaticus infection status, expression levels of proinflammatory IL-17
in cecal tissue was increased in C. rodentium inoculated compared to uninoculated mice at 1
WPI, P < 0.05 (Figure 5-10). Other proinflammatory mediators (TNF-a, IFN-y, MCP-1) trended
higher for C. rodentium alone, whereas anti-inflammatory mediators (TGF-p and IL-10) and
transcription factor Foxp3 trended towards lower expression, but were not significant (Figure 5-
10). In comparison with mice persistently infected with H. hepaticus that were challenged with
C. rodentium, TNF-a expression was higher at 1 WPI and IL-10 was lower at 3 WPI in
Helicobacter-free mice. Cytokine expression was also measured in the mesenteric lymph nodes
(MLN) to determine whether changes were occurring in the draining lymph nodes. Again,
expression levels did not change more than 10-fold in the MLN, however several differences
were apparent between H. hepaticus infected and Helicobacter-free mice inoculated with C.
rodentium, including decreased levels of IL-17 (at 1 and 3 WPI) as well as MCP-1 at 3 WPI and
IFN-y at 1 WPI (Figure 5-10). Spearman correlation of cecal disease indices with cytokine
expression levels revealed that cecal disease was positively correlated with increased
proinflammatory cytokines (of innate, Thl and Thl 7 lineages) and negatively correlated with
anti-inflammatory cytokines (Figure 5-11).
Discussion
The role of naturally-occurring regulatory T cells in the normal colon as well as in
disease has yet to be clarified (1, 58, 77). In the normal gastrointestinal tract, in the absence of
inflammation, nTreg are thought to limit innate and adaptive immune activation by dietary
components and commensal microbiota (14, 58, 80). In situations where inflammation develops,
nTreg cells may serve to limit collateral damage to adjacent tissue. This hypothesis is supported
by recent studies in tuberculosis patients and colitis patients where nTreg cells have been shown to
accumulate at the site of disease (11, 66, 67, 79). Here we demonstrate that infection with C.
rodentium causes a significant increase in the number of nTreg in the colon during established,
active disease. These nTreg could be recruited because they react to C. rodentium antigens, self-
antigens, or even the commensal microflora. However, the temporal distribution of nTreg
suggests they play a role in suppressing inflammation generated in response to C. rodentium.
These findings confirm and extend the findings of Uhlig et al. that showed increased numbers
Foxp3* cells in colon tissue from active infectious colitis and IBD colitis, and validates C.
rodentium as a model for studying human infectious colitis and IBD (79).
In addition to nTreg accumulation during active disease, C. rodentium lesions were
strongly associated with Th1 cytokines in the colon.. Previous studies have also shown a
requirement for Th1 cytokines in C. rodentium disease development (6, 34, 75). A recent study
however, highlighted a potential role of Thl 7 cells in host protection from mortality and disease
development, as mice lacking IL-23 (IL-23p19-deficient mice) died within 2 WPI. (55)
Although exhibiting high mortality, the mice lacking IL-23, a cytokine required for maintenance
of Thl 7 cells, did not develop disease comparable to wild type C57BL/6 mice by 8 DPI. Mangan
et al. also found increased numbers of IL-17 producing T cells (Thl 7 ) compared with IFN-y
producing T cells (Th1 in the colonic lamina propria at 8 DPI. The finding of a strong
correlation between Th1 cytokines and disease severity along with a lack of correlation with Th17
cytokine expression is not in contradiction to the results of Mangan et al. In the current study,
IL-17 expression was strongly induced by 1 WPI indicating a role for IL-17 early during
infection. IL-17 has been shown to recruit neutrophils to mucosal infection sites (57, 92). Mice
deficient in IL-23 would not maintain a population of IL-17 producing Thl 7 cells resulting in
decreased IL-17 production and neutrophil recruitment. Since neutrophil produce signals to
enhance Th1 responses, this lack of recruitment could be detrimental to the host, if Th cells are
needed for proper host response to C. rodentium.
In this mouse model of colitis, the presence of a persistent H. hepaticus infection resulted
in slight suppression of C. rodentium-induced ThI cytokines during maximal disease.
Appreciably prolonged disease (clinically and histologically) was associated with a modest
increase in IL-17 expression, as well as sustained marked elevation in nTreg cells. Increased IL-
17 expression in mice concurrently infected with H. hepaticus could be due to increased IL-17
on a per cell basis or non-helper T cell sources. However, an expanded Th1 7 cell population as a
result of the lower IFN-y is more likely because IFN-y has been shown to suppress Th17 cell
generation. Lower Th1 cytokine production would allow for an increase in the Th17 cell
population, in concordance with what is observed with H. hepaticus infected mice during C.
rodentium infection.
The suppression of Th1 cytokines associated with concurrent H. hepaticus infection may
be attributable to inducible regulatory T cells (IL-10 producing TR1 cells) rather than nT,,,, as
increases in nTreg cells occur too late to explain the reduced Th1 host response that has been
shown to be associated with active disease. Several CD4* regulatory T cell populations are
thought to exist in vivo, including Th3 , thymus-derived naturally-occurring regulatory T cells
(nTreg) that are CD25*Foxp3*, and T regulatory-I (TR) that are induced upon antigen exposure
(1, 77). H. hepaticus infection has been shown to induce a population of CD4*CD25- T cells
with a regulatory phenotype dependent on IL-10 that are likely TRI, however to-date there are no
markers exclusive to this regulatory T cell subset (41). IL-10 has been shown to inhibit ThI
cells, therefore suppression of the C. rodentium-induced Th1 response may be due to IL- 10
secretion from TRI cells as a result of persistent H. hepaticus infection (41). Although this study
did not find elevated IL-10 mRNA expression in H. hepaticus infected mice, other studies have
shown induction of IL-10 mRNA upon H. hepaticus infection, as well as demonstrating the
functional importance of IL-10 during H. hepaticus infection (8, 19, 41-43). A detailed analysis
of the lamina propria lymphocyte populations throughout the duration of C. rodentium infection
with and without H. hepaticus and correlation with disease state would help determine the roles
of different T cell subsets and their cytokine secretion in disease progression.
This study demonstrates that concurrent infections not only modulate the Thl -Th2
balance, but the Thl-Th17 balance as well, causing a different disease outcome (10, 25). A
previous study showed helminth infection (Th2-biased) during C. rodentium infection resulted in
sustained bacterial burden with increased mortality (10). This altered outcome may be due to a
shift in Thi (or even Thl 7 ) responses to C. rodentium to inappropriate Th2 responses.. Similarly
H. hepaticus alters the balance of IL- 17-producing and IFN-y-producing T cell populations in
response to C. rodentium infection. This shift in Thl-Thl 7 balance occurs through modest
suppression of Thl responses that allows for enhanced expansion of Thl 7 cells. Associated with
the shift in Thl-Thl7 balance is prolonged disease exhibited by a delay in weight re-gain and
lesion resolution. Additionally, modulation is caused by a persistent subclinical pathogen that
would not be detected unless specifically tested for its presence. These findings highlight the
impact that undetected infections can have on host response to clinical infections and disease
outcome. Persistent subclinical infections may partially explain the diversity of responses people
have to acute infections. However, additional studies are required to assess the potential
spectrum of roles persistent infections, such as H. pylori, Mycobacterium tuberculosis, etc. in
humans, play in altering host responses to unrelated pathogens. In this model system, host-
pathogen interactions during polymicrobial infections can be investigated, as well as the role of
subclinical bacterial infection in modulation of inflammatory bowel disease and irritable bowel
syndrome.
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Figure 5-1. Persistent H. hepaticus infection impairs recovery of weight loss without
changing kinetics of C. rodentium bacterial shedding. C. rodentium bacterial burden (A)
reached a maximum by 2 WPI followed by clearance during weeks 3 and 4. Persistent H.
hepaticus infection did not affect C. rodentium bacterial burden. Weight loss (B) did not occur
in uninoculated or H. hepaticus infected mice, where as mice inoculated with C. rodentium lost
up to 5% of their initial body weight by 2 WPI followed by rapid weight regain, becoming
comparable to uninoculated mice by 3 WPI. Weight loss in mice with a persistent H. hepaticus
infection inoculated with C. rodentium was comparable to Helicobacter-free mice with C.
rodentium. However, persistently infected mice did not regain their weight by 4 WPI. Data are
represented as mean ± SEM. Two-way ANOVA with Bonferroni post-test, ** P < 0.01.
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Figure 5-2. Pathogen-specific
immunoglobulin titers are not affected
by persistent H. hepaticus infection.
Infection with H. hepaticus leads to
development of humoral immune
response with H. hepaticus-specific IgGI
and IgG2c titers that were not different
between H. hepaticus singly-infected and
mice also infected with C. rodentium for
one week (A). C. rodentium infected
mice, regardless of Helicobacter status,
develop comparable specific humoral
immune responses (IgG2c and IgGI)
against C. rodentium by 3 WPI (B).
Development of C. rodentium-specific
IgM after three weeks of infection was
not significantly modulated by an
ongoing H. hepaticus infection (C, left
Y-axis). Secretion of IgA, specific to H.
hepaticus, into the cecal lumen in mice
also infected with C. rodentium for 1
week was equivalent to H. hepaticus
singly-infected mice (C, right Y-axis).
Bars indicate group mean value.
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Figure 5-3. C. rodentium infection causes marked colon disease that is prolonged by
persistent H. Aeprticus infection. (A) Box-whisker plot of disease index attained by summing
colonic inflammation, edema, hyperplasia, dysplasia, and epithelial defects each assessed on a
scale of 0 to 4. ***,p <0.001 (two-way ANOVA with Bonferroni post-test). (B-F)
Representative (median disease index) Hemoxylin and Eosin stained colon from H hepadics 3
months post-H Aepaicus inoculation (B), C. rodeindum 2 WPI (C), H Aepauics and C.
rodentium 2 WPI (D), C. rodenduim 4 WPI (E), and H Iepadcus and C. rodentium 4 WPI (F).
Scale bar = 160 sim (B-F).
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Figure 5-4. Persistent H. Aeputicus infection maintains elevated numbers of Foxp3
expressing cells in colonic tissue as a result of C. rodentium infection. (A) Numbers of
Foxp3* cells in colon over 4 WPI. ***P <0.001 (two-way ANOVA with Bonferroni post-test).
(B-E) Representative photomicrographs of Foxp3 stained colon from C. rodenium 3 WPI (B),
H hepaticus and C. rodeAtium 3 WPI (C), C. rodenium 4 WPI (D), and H hepaticus and C.
rodentium 4 WPI (E). Error bars in (A) represent SEM. Scale bar = 40 pim (B-E).
100000
10000-
1000-
100.
10-
1 -
0.1.
0.01.
.IrV~Vyv
10000 -
1000-
100-
10.
1 -
0.1.
0.01
100000-
z
cc
E
0
U-
Figure 5-5.
10000.
1000 -
100-
10.
1 -
0.1.
IFN-y
IL-12p35
IL-12/23p40
0.01 1 1
C. ro dentfum H. hepaacUs +C rodenium
Persistent H. hepaticus infection
100000
10000.
1000-
100-
10.
1-
0.1-
0.01.
100000.
10000-
IL-1 7
%
V a M
* At
.. . . . . . .. . . . . . .
IL-23p19
10004
100-
10.
1:
0.1.
0.01.
100000
10000.
1000.
100.
10.
1.
0.1.
A
A
A
TNF-cc
0.01 1
C. radetlum H. hepagcws+C. rodfod
suppresses the Th1 pro-inflammatory cytokine
profile induced after C. rodentium infection resulting in higher IL-17 (Th1 7) expression at 4
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TNF-a were measured by qRT-PCR. Squares (U, LI) are expression levels at 1 WPI; triangles
(A, A) are 2 WPI; diamonds (*, O) are 3 WPI; and circles (0, 0) are 4 WPI. *P < 0.05 (two-
way ANOVA with Bonferroni post-tests).
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Figure 5-6. Changes in colonic mRNA expression levels of other colitis-associated factors
were either not affected by C. rodentium infection or concurrent persistent H. hepaticus
infection. Colonic expression of TGF-p, IL-10, IL-6, IL-1p, MCP-1, Foxp3, and Mylk (MLCK)
were measured by qRT-PCR. Squares (U, EI) are expression levels at 1 WPI; triangles (A, A)
are 2 WPI; diamonds (*, K) are 3 WPI; and circles (0, 0) are 4 WPI. *P <0.05 (two-way
ANOVA with Bonferroni post-test).
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Figure 5-7. Colonic disease severity is positively correlated with IFN-y expression, not IL-
17 expression. Spearman correlation of the colon disease index and corresponding IFN-y or IL-
17 mRNA expression demonstrated a positive correlation between colonic disease severity and
IFN- y expression (Spearman r = 0.763, P <0.0032), but no correlation between colonic disease
severity and IL-17 (Spearman r = 0.097, P > 0.05). Solid lines are linear regression of colon
disease and cytokine expression, not spearman correlation, to aid visualization of correlation.
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Figure 5-8. Early during C. rodentium infection cecal disease was apparent, yet when the
cecal apex was not included in evaluation persistent H. hepaticus infection prevented
disease. When cecal apex was excluded from evaluation, cecal disease (A) was present in C.
rodentium inoculated mice compared with H. hepaticus infected, and mice concurrently infected
with H. hepaticus at 1 week and 2 weeks. Cecal disease in C. rodentium inoculated mice was
equivalent to C. rodentium uninoculated mice by 3 WPI. When the apex of the cecum was
evaluated (only at 1 WPI) (B) C. rodentium-induced disease was observed in mice regardless of
Helicobacter status. *** P < 0.001, two-way ANOVA with Bonferroni post-test.
E 30-
25-
CJ
E
E
620.
+ 15.
10.
5-
Uninfected H. hepatics C. rodentium C. rodentium+
H. hepaticus
Figure 5-9. Foxp3*cell numbers in the cecum did not change with H. hepaticus, C.
rodentium, or concurrent infection. Compared with the basal number of Foxp3* cells in the
cecum, H. hepaticus infection did not cause a change in number. Between 1 WPI and 4 WPI C.
rodentium infection did not affect cecal numbers of Foxp3* cells. No synergistic effects of
persistent H. hepaticus and C. rodentium infection were observed with Foxp3* cell numbers. P
0.05 was considered significant, two-way ANOVA with Bonferroni post-test.
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Figure 5-10. C. rodentium infection caused modest changes of cytokine expression in the
MLN and the cecum with slight suppression of pro-inflammatory cytokines seen with
persistent H. hepaticus infection. MLN mRNA expression levels of MCP-1, IL-17, and IFN-y
were decreased when mice were persistently infected with H. hepaticus, along with cecal TNF-a
levels. IL-10 expression in the cecum increased with persistent H. hepaticus infection.
However, in comparison to colonic expression, MLN and cecal mRNA expression levels were
modest. Squares (U, E-1) are expression levels at 1 WPI; triangles (A, A) are 3 WPI. *P <0.05,
** P < 0.01 (two-way ANOVA with Bonferroni post-test).
3-
2-
z
E
-2- -J -2-
C D IL-10 * TNF-u
- A TGF-p IFN-y
.
xw
z
cc
E
o *o
LL 0
00
0
..J
1 2 3 4 5 6 7 8 9 10
Cecal Disease Index
Figure 5-11. Cecal disease severity at 1 WPI is positively correlated with proinflammatory
cytokine expression, and negatively correlated with anti-inflammatory cytokine expression.
Spearman correlation of the cecal disease index and corresponding IFN-y or TNF-a mRNA
expression demonstrated a positive correlation between cecal disease severity expression of each
proinflammatory cytokine (Spearman r = 0.624, P < 0.01 and r = 0.516 P < 0.05, respectively).
The anti-inflammatory cytokines TGF-p and IL-10 had negative correlations with cecal disease
severity at 1 WPI, although they were not significant (Spearman r = -0.363, P > 0.05 and r = -
0.240, P > 0.05, respectively). However, Foxp3 expression was significantly negatively
correlated with cecal disease severity (Spearman r = -0.519, P <0.05). Lines are linear
regression of cecal disease and cytokine expression, not spearman correlation, to aid
visualization of correlation.
Chapter 6
Conclusions
Persistent, subclinical infections are prevalent throughout the world, often unbeknownst
to the host unless clinical disease develops. However, the host's immune system keeps the
infections under control through careful regulation, likely via regulatory T cells, which evolved
to minimize damage and benefit both host and pathogen. The resulting regulation may cause
subtle changes to the hosts' response to other stimuli by suppressing immune responses.
Helicobacter pylori is one such organism, residing in the stomachs of approximately 50% of the
world population yet causing clinical gastritis in only a small fraction of infected individuals. H.
pylori elicits a host response that includes immunomodulatory regulatory T cells, which have the
ability to suppress the host response. The subclincal persistent murine intestinal pathogen,
Helicobacter hepaticus, closely related to H. pylori, is enzootic in mouse research colonies
throughout the world. When regulatory functions of the immune system are absent from the
host, IBD-like disease develops in the lower bowel of H. hepaticus infected mice. This H.
hepaticus-dependent disease has been characterized, and develops with or without effector T
cells, implicating both innate and adaptive immunity in the disease process. Additionally, in the
susceptible A/J strain of mouse, H. hepaticus causes hepatitis, hepatocellular carcinoma, and
mild lesions in the lower bowel. Differences in host immune responses between disease-resistant
C57BL/6 mice and disease-susceptible A/J mice have not been evaluated. The immune response
(tissue cytokines and specific antibodies) to H. hepaticus in the disease-resistant C57BL/6 mice
was measured early and late during infection, then compared with the disease-susceptible A/J
mice at the late time point when disease is present.
To test the hypothesis that host-pathogen interactions during H. hepaticus infection of
C57BL/6 mice prevents the tolerogenic host responses to soluble oral antigen, disrupts
immunogenic protection from acute enteric infection, and host response to enteric infection, the
immunomodulatory potential of H. hepaticus was evaluated using the model food antigen
ovalbumin (OVA), and the murine pathogen Citrobacter rodentium, a mouse model of
enteropathogenic Escherichia coli (EPEC) infection.
Infection of C57BL/6 mice with H. hepaticus for up to 6 months results in no clinical signs or
disease development. To confirm that H. hepaticus infection remained subclinical due to
minimal immune activation at the site of infection, histological evaluation of cecal and colonic
tissue, cytokines expression levels and antibody titers were compared at 2 months and 18 months
post-inoculation. Minimal histological changes in the cecum and no lesions in colon or liver
were observed in C57BL/6 mice infected with H. hepaticus after 18 months. At 2-3 MPI
colonic, MLN, and cecal cytokine expression levels were equivalent to uninoculated C57BL/6
control mice, except for a significant increase in cecal IL-17 mRNA. Cecal tissue cytokines at 18
MPI remained equivalent to uninoculated age-matched C57BL/6 mice, as well as the levels
measured at 2-3 MPI. Additionally, comparison of cytokine levels of C57BL/6 mice 18 MPI
with matched samples from susceptible A/J mice revealed significant strain differences with
increases of both pro-inflammatory as well as anti-inflammatory cytokines in the Helicobacter-
free A/J mice. Infection of A/J mice for 18 months resulted in a broad decrease in cecal cytokine
expression compared with Helicobacter-free A/J mice. Overall, C57BL/6 mice have low
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background levels of cytokines compared with A/J mice throughout their infection with H.
hepaticus that correlate with the lack of tissue damage.
Oral vaccines are attractive to manufacture because mucosal immunity is the first line of
defense against most pathogens, and they have better patient compliance due to the ease of
delivery. Complicating the design and development of oral vaccines, is natural immunologic
non-responsiveness to exposure of antigen at the mucosal surface either through tolerance or
ignorance. Oral delivery of soluble antigen not in the context of an adjuvant leads to tolerance,
rather than immunity. Using a model of oral tolerance to investigate the immunomodulatory
effects of a concurrent infection by acting as an adjuvant in the mucosa, the ability of subclinical
H. hepaticus infection to influence tolerance to the soluble antigen OVA was investigated.
Previous studies demonstrated that enteric helminth infection acts as an adjuvant, priming for a
Th2-biased response to soluble OVA (71, 72). A comparable Th1 adjuvant effect was mediated
by H. hepaticus when feeding OVA to infected mice, as persistent infection with H. hepaticus
primed for a systemic IFN-y response to a single high-dose of intragastrically administered
OVA. In the same study, in vivo assessment of tolerance, OVA-specific IgG2c antibody titers,
were also not tolerized in mice with a subclinical H. hepaticus infection. When OVA was
administered at a high-dose continuously, robust oral tolerance was induced as evident by a
complete shutdown of OVA-specific recall responses ex-vivo. H. hepaticus infection was not
able alter the tolerogenic host responses elicited by continuous high-dose feeding of OVA,
indicating continuous feeding may induce oral tolerance outside the gastrointestinal tract.
Additionally, IL-10 was not required for tolerogenic host responses, as OVA-specific responses
in IL-10-deficient mice were comparable to wild-type mice. Thus, the ability of enteric
pathogens to influence immunologic responses to a model dietary antigen is not limited to Th2
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polarizing infections, and does not depend on IL-10 signaling or the establishment of an
inflammatory cell infiltrate at the site of antigen uptake, as H. hepaticus infection in wild type
C57BL/6 mice is subclinical. These findings have implications for understanding the basic
mechanism of oral tolerance as well as for possible immunomodulatory consequences of
persistent subclinical infections with Helicobacter species. In addition, these studies suggest
continuous feeding of antigen at a high dose would be the best option when using oral tolerance
therapy for autoimmune diseases in populations that may have subclinical gastrointestinal
infections.
In addition to priming, instead of tolerance, persistent infections may interfere with
development of immunogenic responses, which are essential for successful vaccination. Acute
diarrheal disease is a major world health problem with successful vaccines for only a few of
infectious agents. Enteropathogenic Escherichia coli (EPEC) infection is a common cause of
diarrheal disease for which effective vaccines have yet to be developed. The influence of a
persistent infection on development of protective immunity to EPEC was determined using C.
rodentium as a model of EPEC infection and H. hepaticus as a model of persistent infection.
Mice developed antibodies specific to C. rodentium after immunization with C. rodentium
proteins, however the mice were not consistently protected from infection or disease.
Convalescent mice do have sterilizing immunity, as judged by the lack of infection, clinical
weight loss, and disease development upon re-challenge. Persistent H. hepaticus infection did
not interfere with development of protective immunity from C. rodentium infection as H.
hepaticus infected mice had comparable bacterial burdens, weight, and disease as Helicobacter-
free mice. It is possible that immunity to C. rodentium is too strong to be blocked or altered by
another infection. In the current model persistent underlying infections do not appear to interfere
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with immunity acquired through infection, although their ability to alter immunogenic responses
to vaccines remains undetermined.
Modulation of host response to acute diarrheal infection by a persistent underlying
infection was evaluated using H. hepaticus and C. rodentium as model of persistent subclinical
infection during an acute diarrheal infection. Persistent subclinical H. hepaticus infection
resulted in prolonged C. rodentium-induced disease. During acute disease expression of Thl pro-
inflammatory cytokines were slightly suppressed in mice with an underlying infection. These
persistently infected mice had appreciably delayed disease resolution. Associated with delayed
resolution was a lack of weight re-gain and a markedly sustained presence of colonic Foxp3*
regulatory T cells. A modest increase in colonic IL-17 expression was also observed. Both
Thl 7 cells and Foxp3* regulatory T cells have been associated with chronic inflammation,[*ref,
Uhlig] indicating persistent subclinical infections may contribute to intestinal inflammation
commonly observed in developing countries.
The consequences of persistent infection are broad, including possible prevention of oral
tolerance and prolongation of acute disease. As many subclinical infections go undetected,
variations in host responses to vaccines or other infections could be the result of a persistent
infection with an immunomodulatory subclinical pathogen, such as H. hepaticus in mice or H.
pylori in humans. The host-pathogen interactions that have evolved to dampen overt pathology
to these organisms are able to modulate host responses to other antigens via the cytokine
environment, which may result in different helper T cells populations, or suppression of host
response through regulatory T cells. These studies establish mouse model systems suitable for
further evaluation of the immunologic and clinical consequences of persistent subclinical
infections.
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Chapter 7
Materials and Methods
Bacterial cultures and inoculations
H. hepaticus 3B1 (ATCC 51449) were grown on tryptic soy agar supplemented with 5% sheep
red blood cells or tryptic soy broth (TSB) supplemented with 5% fetal calf serum at 37*C in a
microaerobic environment (80% N2, 10% H2 and 10% C0 2). Bacteria used for inoculation were
visualized by phase contrast and dark field microscopy to confirm the purity and the viability of
the cultures. Inocula were prepared from 2- to 3-day liquid cultures that were centrifuged (10
minutes, 8,000 rpm) and re-suspended in TSB to an optical density of 1.0 at 600 nm (108 CFU).
Mice were inoculated with 200pR of inocula intragastrically using a 24-gauge ball-tipped gavage
needle. Control mice were inoculated with sterile TSB. Infection status was confirmed with H.
hepaticus-specific PCR on fecal DNA from individual mice as previously described (94). For C.
rodentium infections, mice were gavaged with -2x10 9 of an o/n culture of C. rodentium
(DBS 120 kanr, DBS 129 strep' or DBS 135 tet') in 100. LB broth 7 to 8 weeks post-H. hepaticus
infection. C. rodentium fecal shedding was determined by serial dilution plating of fecal slurries
(10 d/mg feces) on LB agar with selection for antibiotic marked strain.
Animals and study designs
Male and female C57BL/6J mice (5-12 weeks of age) were purchased from The Jackson
Laboratory (Bar Harbor, ME). The mice were provided with rodent diet and water ad libitum and
housed in microisolator cages that were maintained in facilities approved by the Association for
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Assessment and Accreditation of Laboratory Animal Care. Until experimentally infected, the
mice were maintain specific-pathogen-free including all known Helicobacter spp. At indicated
time points mice were euthanized by CO2 asphyxiation for tissue collection.
Oral tolerance studies. Female C57BL/6J mice age 6-8 weeks were used. Female and male
C57BL/6 IL10-'- mice (4-6 weeks of age) were a gracious gift from M. Whary (MIT). Either four
weeks or 7 to 8 weeks post-inoculation (WPI), mice were fed ovalbumin (OVA) followed by
immunization with OVA in Complete Freud's Adjuvant (CFA) one week later. Three weeks
after immunization, serum was collected and mice were euthanized.
Vaccine study. Male and female C57BL/6J mice age 5 weeks at study onset. The study
included five groups each consisting of 5 female and 5 male mice. The treatment groups were as
follows: vehicle+LB; vehicle+C. rodentium; s.c. prime/oral boost+LB; s.c. prime/oral boost+C.
rodentium; and s.c. prime/s.c. boost+C. rodentium. S.c. prime/oral boost groups received s.c.
immunization on day 0 followed by oral boosting on days 14, 16, and 18. S.c prime/s.c. boost
received s.c. prime on day 4 and s.c. boost on day 11. Pre-challenge serum was collected the day
prior to challenge. Mice were inoculated with DBS 120 or LB broth 4 weeks (Day 28) after first
immunization. At 14 days post-inoculation (DPI), serum was collected and mice were
euthanized for tissue collection.
Protective immunity pilot study. Male and female, 10 each, C57BL/6J mice age 6 weeks at
study onset were used. Five males and five females were inoculated with LB broth and the
remainder with DBS 120. At 43 DPI, all mice were challenged with DBS 135. All 20 mice were
euthanized 11 days later (54 DPI) for tissue collection. Serum was collected at 14, 28, and 54
DPI.
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Protective immunity with H. hepaticus study. Study consisted of 50 female C57BL/6J mice
C57BL/6 mice age 6 weeks at study onset divided in the six groups: TSB+C. rodentium+LB
broth (n = 5); H. hepaticus+C. rodentium+LB broth (n = 5); TSB+LB broth+C. rodentium (n =
10); H. hepaticus+LB broth+C. rodentium (n = 10); TSB+C. rodentium+C. rodentium (n = 10);
and H. hepaticus+C. rodentium+C. rodentium (n = 10). Four weeks after inoculation with TSB
or H. hepaticus, mice were inoculated with LB broth or DBS 120. At 28 DPI, mice were
challenged with either LB broth or DBS 129. Serum was collected at 21, 27 and 49 DPI (21 DP-
2nd inoculation) when all mice were euthanized for tissue collection.
Concurrent H. hepaticus and C. rodentium infections studies. Male and female C57BL/6J mice
age 5-12 weeks were used. For each study the mice were divided into four infection groups:
uninoculated (n = 10); H. hepaticus (n = 10); C. rodentium (n = 10); and H. hepaticus+C.
rodentium (n = 10). Five studies were conducted: two with euthanasia at 6 DPI (1 WPI); one
with euthanasia at 11 DPI (2 WPI); one with euthanasia 21 DPI (3 WPI); and one with
euthanasia at 27 DPI (4 WPI). Serum was collected at time of euthanasia.
Survival and body weight measurements
Body weights were monitored on indicated days post-C. rodentium infection to evaluate
systemic effects of the bacterial infections. Mice were euthanized by CO2 asphyxiation as
necessary (20% body weight loss).
Tissue collection and Histopathology
Draining popliteal and inguinal lymph nodes (PLN), and mesenteric lymph nodes (MLN) were
harvested under sterile conditions for re-stimulation assays. Cecal contents and colon fecal
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pellets were collected for fecal sIgA or infection confirmation. MLN, cecal apex (-0.5cm) and
distal colon (-0.5cm) were snap frozen in liquid nitrogen and stored at -80*C until RNA
isolation. Remaining colon and cecum were fixed in 10% formalin, paraffin embedded, and
stained with hemoxilyn and eosin for histological evaluation. Cecal and colonic tissue sections
were scored on a scale of 0-4 (where 0 = no lesion, 1 = minimal, 2 = mild, 3 = moderate, and 4=
severe) for inflammation, edema, hyperplasia, dysplasia, and epithelial defects by a board-
certified blinded pathologist (A. Rogers or B. Rickman). Lesion scores are, in places, presented
as tissue disease indices that are a sum of all five categorical scores. Foxp3
immunohistochemistry was performed with Foxp3 primary antibody (FJK-16S, eBiosciences) by
DCM Histology Laboratory staff. Numbers of mucosal tissue Foxp3 expressing cells were
counted in the cecum (starting from ileocecal junction) and distal colon (starting closest to
rectum), excluding gut-associated lymphoid tissue when possible. Ten fields at 20X
magnification were counted per tissue per mouse with 3 to 4 mice per group.
C. rodentium immunizations
C. rodentium protein homogenate was prepared from a 500mL o/n culture that was pelleted,
washed, resuspended in lOmL PBS, and homogenized twice at >10,000psi. Homogenate was
spun down to remove cell membranes and insoluble proteins followed by syringe filtering
(0.2[im filter). Protein concentration of the homogenate was measured by Lowry assay
according to manufacturer's protocol (Pierce). Each subcutaneous injection consisted of 200 g
C. rodentium protein homogenate in PBS:Imject Alum (1:1) with a total volume of 100[d total
volume. Vehicle/adjuvant control mice received 100[l of PBS:Imject Alum (Pierce). For oral
boosting, each mouse received 225kg C. rodentium protein homogenate and 5pg Cholera Toxin
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in PBS with a total volume of 1001d via intragastric gavage. Vehicle/adjuvant control mice
received 5[tg Cholera Toxin in 100t1 PBS.
Oral antigen administration and peripheral immunization
For the single high-dose experiments, 4 to 7 weeks post-H. hepaticus infection, 0.25 ml of either
PBS or ovalbumin (OVA) grade V (25 mg in PBS; Sigma-Aldrich) was administered
intragastrically. Control mice received PBS or OVA without concurrent H. hepaticus infection.
For the continuous antigen feeding experiments, 4 to 7 WPI, animals were offered, ad libitum, a
1% OVA grade II (Sigma-Aldrich) solution dissolved in drinking water for 5 consecutive days or
standard drinking water as described previously (59). Control mice received 1% OVA grade II
solution or standard drinking water in the absence of H, hepaticus infection. For both single and
continuous high-dose feeding experiments, one week after the first feeding, mice were
immunized in the hind footpads with 40[d of 100 [tg of OVA in Complete Freund's Adjuvant
(CFA) (Sigma-Aldrich).
In vitro re-stimulation
Pooled PLN cells from each group of four or five mice were cultured in 48-well flat bottom
plates at 2.5x106 cells/well in 1ml of complete DMEM (Invitrogen; complete DMEM contains
10% FCS, 10 mM HEPES, 2 mM L-glutamine, 100 U penicillin/ml, 100 mg streptomycin/ml, 50
mM b-mercaptoethanol, 0.1 mM nonessential amino acids, and 1 mM sodium pyruvate) with 0,
10, 10O g/ml of OVA or purified anti-CD3 (5[tg/ml R&D Systems).
Measurement of cytokine production
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After 72 hours of culture, supernatants were collected and frozen at -200C until analyzed for
levels of IFN-y and IL-13 by ELISA as previously described (70, 72). For IFN-y assays,
Immulon II plates (Dynatech Labs) were coated with anti-IFN-y capture antibody (R4-6A2, BD
PharMingen) overnight at 44C, followed by blocking in PBS with 3% FCS at 37*C for 1 hour.
After washing with PBS-Tween (0.05% Tween 20), the culture supernatants or recombinant
murine IFN-y (BD PharMingen), were incubated in triplicate for 1 hour at 370C. Plates were
then washed and incubated with biotinylated anti-IFN-y secondary antibodies (XMG1.2, BD
PharMingen), followed by peroxidase-conjugated streptavidin (Invitrogen) and developed with
O-phenylenediamine (Invitrogen) or TMB (Pierce). Reactions were stopped with 2N H2SO 4 and
the plates were read at 490nm (0-phenylenediamine) or 450nm (TMB) using an Emax
microplate reader (Molecular Devices). IL- 13 was measured with a DuoSet ELISA development
kit for the detection of murine IL-13 according to the manufacturer's instructions (R&D Systems).
The concentrations of cytokine in each sample were calculated from standard curves using
SOFTmax PRO software (Molecular Devices).
Antibody titers
OVA. OVA-specific IgG 1 and IgG2c titers in serum collected at sacrifice from individual mice
were measured with ELISAs. OVA-coated Immulon II plates were blocked with PBS/3% FCS
for 1 hours at room temperature (RT) and washed in PBS/Tween 20 before addition of diluted
serum samples, in triplicate. After 2 hours at RT, isotype specific antibody responses were
detected using horseradish peroxidase conjugated goat anti-mouse IgG1 and IgG2c (Southern
Biotech). The reaction was developed with TMB and read at 450 nm. OD values were
converted to mg/ml of OVA-specific IgG1 or IgG2c.
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H. hepaticus, C. rodentium, and total immunoglobulin. Total and bacteria-specific fecal sIgA,
and serum IgM, IgG1, and IgG2c were measured by ELISA. Total antibody titers were
measured according to manufacturers' protocol (BD PharMingen). Unlabeled and biotin-labeled
matched antibody pairs for IgA (C10-1 and C10-3, BD PharMingen), IgM (11/41 and R6 60.2,
BD PharMingen), IgG1 (A85-3 and A85-1, BD PharMingen) and IgG2c (Southern Biotech)
were used for capture and detection. For bacteria-specific titers, sample wells were coated with
either C. rodentium (1:20 in PBS) or 100[tg H. hepaticus outer membrane preps in coating buffer
prepared as described previously (87). Titers in diluted serum were quantified by OD value
comparison to standard curves of purified mouse IgA (S 107, Southern Biotech), IgM (1 1E0,
Southern Biotech), IgG1 (MOPC-31C, BD PharMingen) and IgG2c quantitated serum
(550Vg/ml, Bethyl Laboratories).
Q-PCR
Total RNA was isolated from distal colon, cecal tip, or MLN using TRIzol reagent (Invitrogen),
cleaned with RNeasy Kit (Qiagen), and reverse transcribed (Invitrogen) following
manufacturers' protocols. Quantitative real-time PCR was performed on cDNA using TaqMan@
Gene Expression Assays (Applied Biosystems) specific for murine GAPDH (Mm99999915_g1),
IL-4 (Mm99999154_ml), IL-13 (Mm00434204_ml), IL-10 (Mm00439616_ml,
Mm99999062_ml), TGF-p (Mm00441724_ml), TNF-a (Mm99999068_ml), IFN-y
(Mm99999071_ml), IL-12/IL-23p40 (Mm99999067_ml), IL-12p35 (Mm01208555_ml), IL-
23p19 (Mm00518984_ml), IL-6 (Mm00446190_ml, Mm99999064_ml), IL-17
(Mm00439619_ml), MCP-1 (Mm00441242_ml), IL-1p (Mm00434228_ml), Foxp3
(Mm00475156_ml), and Mylk (MLCK, Mm00653039_ml). Each sample was normalized to
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internal GAPDH levels and to the average of control (uninoculated mice) samples at the same
time point.
Statistics
Statistical significance in bacterial counts, weight change, and disease indices were determined
by two-way ANOVA, Kruskal-Wallis followed by Dunn's post-test, Mann-Whitney, or unpaired
two-tailed Student's t test where appropriate. Cytokine production in re-stimulation assays and
antibody titers were evaluated for statistical significance by one-way ANOVA with Bonferroni
post-tests. Statistical differences in mRNA expression were evaluated by two-way ANOVA for
all time points and infection statuses followed by Bonferroni post-tests. Spearman correlation
was used to evaluate correlation between disease indices and cytokine mRNA expression levels.
All analyses were done with GraphPad Prizm Software version 4.0. P values of < 0.05 were
considered significant.
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